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Abstract. The association of Apolipoprotein E (APOE) with late-onset Alzheimer’s disease (LOAD) and cognitive endophe-
notypes of aging has been widely investigated. There is increasing interest in evaluating the association of other LOAD
risk loci with cognitive performance and decline. The results of these studies have been inconsistent and inconclusive. We
conducted a systematic review of studies investigating the association of non-APOE LOAD risk loci with cognitive per-
formance in older adults. Studies published from January 2009 to April 2018 were identified through a PubMed database
search using keywords and by scanning reference lists. Studies were included if they were either cross-sectional or lon-
gitudinal in design, included at least one genome-wide significant LOAD risk loci or a genetic risk score, and had one
objective measure of cognition. Quality assessment of the studies was conducted using the quality of genetic studies (Q-
Genie) tool. Of 2,466 studies reviewed, 49 met inclusion criteria. Fifteen percent of the associations between non-APOE
LOAD risk loci and cognition were significant. However, these associations were not replicated across studies, and the
majority were rendered non-significant when adjusting for multiple testing. One-third of the studies included genetic risk
scores, and these were typically significant only when APOE was included. The findings of this systematic review do not
support a consistent association between individual non-APOE LOAD risk and cognitive performance or decline. However,
evidence suggests that aggregate LOAD genetic risk exerts deleterious effects on decline in episodic memory and global
cognition.
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INTRODUCTION28
Cognitive performance generally declines with29
age, however, the patterns are characterized by 1)30
differences across cognitive domains and 2) substan-31
tial individual variation in level and trajectory [1, 2].32
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Performance on measures of episodic memory, exec- 33
utive function, reasoning, and processing speed may 34
begin to decline in early adulthood whereas gradual 35
improvement in some verbal and knowledge abili- 36
ties may continue to the sixth or seventh decade of 37
life [3]. Variation in individual trajectories reflects 38
life-long differences in demographic, lifestyle, med- 39
ical, environmental, neurobiological, and genetic 40
factors [4]. 41
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Cognitive decline is a multifactorial process that42
is likely promoted by the gradual accumulation of43
neuropathology associated with various chronic con-44
ditions of aging [5–7] and in particular late-onset45
Alzheimer’s disease (LOAD) [8]. The accumulation46
of amyloid- (A) and neurofibrillary tangles (NFT)47
begins decades prior to the onset of the clinical symp-48
toms of LOAD [9–12]. In dementia-free individuals49
a higher burden of LOAD pathology is on average50
associated with reduced cognitive performance and51
faster rates of cognitive decline [13–15]. As such,52
age-related cognitive decline may be mediated by the53
co-occurrence of A, NFT, and other neuropatholo-54
gies [16–18].55
Genetic factors play an important role in the56
development of LOAD, accounting for 53% of the57
total phenotypic variance [19]. The Apolipoprotein58
E (APOE) epsilon (*4) allele was the first com-59
mon genetic variant associated with LOAD [20], with60
recent genome-wide association studies (GWAS)61
identifying a further 26 loci associated with LOAD62
(Supplementary Table 1). GWAS performed sep-63
arately by four LOAD genetic consortia initially64
identified 11 loci (ABCA7, BIN1, CD2AP, CD33,65
CLU, CR1, EPHA1, MS4A4A, MS4A4E, MS4A6A,66
and PICALM) [21–25]. A further 12 loci (HLA-67
DRB5, PTK2B, SORL1, SLC24A4-RIN3, INPP5D,68
MEF2C, NME8, ZCWPW1, CELF1, FERMT2, and69
CASS4) were identified in a meta-analysis by70
the International Genomics of Alzheimer’s Project71
(IGAP) [26]. A meta-analysis of IGAP and a proxy72
GWAS case-control study of self-reported fam-73
ily history of parental Alzheimer’s dementia in74
114 564 (14 482 proxy-cases & 100 082 proxy-75
controls) individuals from the UK Biobank identified76
a further 4 loci (HBEGF, ECHDC3, SCIMP, and77
SPPL2A) [27].78
A trio of recent GWAS have identified a fur-79
ther 16 loci. A second meta-analysis of IGAP with80
an expanded UK Biobank dataset (n= 314 278)81
identified three loci (ADAM10, KAT8, and ACE)82
[28]. A meta-analysis of UK Biobank proxy case-83
control status (n= 376,113), the personality genomics84
consortium Alzheimer’s disease working group of85
the Psychiatric Genomics Consortium (PGC-ALZ,86
n= 17,477), IGAP (n= 54,162), and the Alzheimer’s87
Disease Sequencing Project (ADSP, n= 7,506) iden-88
tified 8 loci (ADAMTS4, HESX1, CLNK, CNTAP2,89
APH1B, ABI3, ALPK2, and ACO74212.3) [29].90
Finally, an expanded IGAP analysis (n= 94,437)91
identified five loci (OARD1, TREM2, IQCK, WWOX,92
and ADAMTS1) [30]. TREM2 and ABI3, however,93
were identified as AD associated loci in an earlier 94
rare variant analysis [31]. 95
There is increasing interest in evaluating the 96
role of LOAD genetic risk variants with cognitive 97
decline. First, the shared cognitive and neuroanatom- 98
ical characteristics of normal cognitive aging and the 99
early stages of LOAD may be mediated by shared 100
genetic mechanisms. The presence of individual 101
LOAD-associated risk loci may lead to diminished 102
overall cognitive function, in the absence of cogni- 103
tive impairment or dementia, mediated by the gradual 104
accumulation of LOAD pathology [13, 14]. Sec- 105
ond, cognitive decline prior to dementia represents 106
an important endophenotype for LOAD. Cognitive 107
domain-specific variance reflects localized regional 108
brain structures/networks and the connectivity of 109
those networks. Therefore, the differential asso- 110
ciation of individual loci with specific cognitive 111
domains may reflect associations with particular neu- 112
roanatomical structures that influence LOAD onset 113
and progression. 114
Initial support for the association of LOAD risk 115
loci with cognitive performance was obtained from 116
studies assessing the association of APOE with cog- 117
nition, where the APOE*4 allele was associated 118
with specific deleterious effects on episodic memory, 119
executive functioning, perceptual speed, and global 120
cognitive ability [32, 33]. Further studies examining 121
the association of other LOAD risk loci with cogni- 122
tive function have been inconsistent and inconclusive. 123
The aim of this systematic review is to evaluate the 124
evidence of the association of non-APOE LOAD 125
risk loci with cognitive performance and decline, 126
within the context of both cognitive aging and a 127
LOAD cognitive endophenotype. We provide a nar- 128
rative synthesis rather than focusing on the relatively 129
few studies that would be amenable to meta-analysis 130
due to the heterogeneity in methodologies between 131
studies. 132
METHODS 133
Registration of protocol and reporting 134
The protocol for the review was registered 135
with the International Prospective Register of Sys- 136
tematic Reviews (PROSPERO CRD42017075685) 137
[34] and the review is reported in accordance 138
with the PRISMA checklist (see Supplementary 139
Material). 140
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Table 1
Study Characteristics
Study Cohort Sample Size Age (y) Education (y) % Male Population Studied Follow-up (y) Cognitive Status
Andrews 2017 [41] PATH 1,626 62.51 (1.51) 14.15 50.46 Caucasian 12 1,626 CN
Barral 2012 [90] NIA-LOAD 1,365 72.9 (8.67) 14.5 (3) 60.1 Caucasian — 337 AD, 1028 CN
Bressler 2017 [44] ARIC 8,320 57 (5.6) >11:86.1% 46.1 Caucasian 6 —
2,039 55.8 (5.7) >11:68.2% 33.7 African-American
Carrasquillo 2015 [42] Mayo Clinic 2,262 77 (49–98)* 14 (4–20)* 44 Caucasian 3.8 (0.7–17.8)* At last diagnosis:
1881 CN, 252
MCI, 129 AD
Chibnik 2011 [57] ROS MAP 791 75.5 (7.3) 18.1 (3.4) 34 Caucasian 7.8 (4.5) 218 incident AD
875 81.0 (6.7) 14.3 (3.2) 27 4.3 (2.6) 186 incident AD
Christoforou 2014 [69] NCNG 670 47.6 (18.3) — 31.8 Caucasian — —
Darst 2017 [68] WRAP 1,200 53.6 (6.6) 16.3 (2.8) 31.1 Caucasian 6.2 CN; enriched with a family
history of AD
Davies 2014 [89] CAGES 3,280 — Caucasian Non-demented
LBC1921</b> 453 79.1 (0.6) 41 68
LBC1936</b> 932 69.5 (0.8) 51 59
ABC1936</b> 347 64.6 (0.9) 52 53
Manchester and 1,548 65 (44–93)* 29 14 (12–18)*
Newcastle
Davies 2015 [61] CHARGE 53,949 66.39 (44.2) — 42.7 Caucasian — 53,949 CN
Davies 2016 [58] UK Biobank 112,151 56.91 (7.93) 30.5% w/ college degree 47.5 Caucasian — —
Davies 2018 [39] UKBB, CHARGE, 300,486 56.76 — 46.26 Caucasian — Dementia Free at baseline
COGENT
Debette 2015 [56] CHARGE 29,076 63.6 (7.0) 28.8% w/ college degree 44 Caucasian — 29,076 CN
DeJager 2012 [78] ROS 749 75.3 (7.2) 18.2 (3.4) 34 Caucasian 9 CN at Baseline. At last diagnosis:
151 MCI; 152 Dementia
Engelman 2013 [43] WRAP 1,153 53.6 (6.6) ≥college 62% 31 Caucasian UTAI 8 CN at baseline; Enriched for a
parental history of AD
Ferencz 2014 [70] SNAC-K 2 480 71.69 (10.3) 12.29 (4.3) 34.1 Swedish — CN at baseline
Ge 2018 [75] ADNI 702 72.8 16.3 54.6 Caucasian 2.83 Baseline: 221 CN; 367 MCI, 114
AD
Gui 2014 [88] GBCS Chinese 4 CN at baseline; 198 incident
Neurological disease
Cases 1 325 62.4 (7.0) ≥College 9% 31.5
Controls 1 083 65.4 (4.5) ≥College 17.1% 32.4
Hagenaars 2016 [95] UK Biobank 112 151 56.9 (7.9) 30.5% w/ degree 47.5 British — —
Hagenaars 2017 [50] UK Biobank 23 822 — — — British — —
Hamilton 2011 [47] LBC1921 505 10.9 (0.28) — 41.3 Caucasian 68.21 CN
LBC1936 998 10.9 (0.28) 50.5 58.68
(continued)
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(continued)
Study Cohort Sample Size Age (y) Education (y) % Male Population Studied Follow-up (y) Cognitive Status
Harris 2014 [96] CAGES Caucasian
LBC1921</b> 550 79.1 (0.6) — 42.5 68.21 CN
LBC1936 1 091 69.5 (0.8) — 50.2 58.68
ABC1936</b> 498 64.6 (0.9) — 48.8 53.7
Manchester and Newcastle 6,063 44–93 — 30.1 20
Hill 2018 [40] UKBB 120 934 — — — — — —
SSAGC 329 417
Sniekers 2017 78 308
Houlihan 2009 [62] LBC1936 1 031 69.5 (0.8) — 50.3 Scottish 58.68 CN
Keenan 2012 [94] ROS 817 75.7 (7.4) 18.2 (3.4) 34.4 Caucasian — Dementia free at baseline, 240
incident dementia
MAP 892 81.1 (6.7) 14.7 (2.9) 27.6 Caucasian 27.8% CN; 48.9% MCI; 23.3%
AD
ADNI 746 75.4 (6.9) 15.6 (3.0) 59 11.6% AD
CHAP 624 71.9 (5.2) 14.9 (3.3) 37 Caucasian
Liang 2015 [97] BABRI 780 64.7 (7.2) 11.3 (3.2) 37.1 Chinese — Cognitively Normal
Liao 2014 [87] Taiwan Biobank 307 76.2 (10) 10.7 (4.9) 69.4 Chinese — Cognitively Normal
Liebers 2016 [73] HRS 8 616 60.5 (8.5) ≥college 25.2% 43.8 Caucasian 10 (0–14) —
Li 2017 [64] BABRI 780 64.7 (7.3) 11.3 (3.2) 37.1 Chinese — CN
Liu 2009 [65] Rotterdam 2 583 64.0 (5.8) — 42.9 Caucasian — CN
Study ERF 2 883 48.7 (14.5) 40.0
Liu 2014 [67] ADNI 211 75.6 (4.9) 16.1 (2.8) 54 — — CN
Marden 2016 [71] HRS 7 172 63.0 (8.4) 13.1 (2.5) 40.8 Caucasian 12.3 —
1 081 61.6 (8.0) 11.4 (3.3) 33.7 African-American 11.3
Marioni 2017 [74] Generation Scotland 3 495 63 (61–65)† 12 (3–15)† 42.8 Scottish — CN
McFall 2016 [92] VLS 593 70.3 (8.66) 15.3 (2.95) 32.7 Canadian UTAI 9 CN
Mengel-From 2011 [54] Danish 1905 Cohort Study 1 380 92–93 — 31 Danish — At baseline: 48.64%
non-impaired; 32.06%
Mildly Impaired; 19.30%
Severely Impaired
Mengel-From 2013 [55] Danish 1905 Cohort Study 1 651 92–93 — — Danish 7 10 At baseline: 47.3% CN
LSADT 573 73–83 At baseline: 80.7% CN
Mormino 2016 [72] ADNI 526 75.3 (6.5) 15.9 (2.9) 61.8 Caucasian 4.58 (2.74) 36.9% CN; 63.1% MCI
Nettiksimmons 2016 [45] MrOS SOF 3 267 73.4 (5.7) 56% w/ college degree 100 0 Caucasian UTAI 10 —
3 026 71.0 (4.9) 18% w/ college degree UTAI 10
Pedraza 2014 [52] Mayo Clinic 268 2 78.7 (7.4) 12.6 (3.0) 23 African American — CN: 224; AD: 44
651 81.8 (6.3) 14.0 (2.9) 43.7 Caucasian CN: 2219; AD: 431
Qiu 2016 [93] — 46 62.96 — 39.1 Chinese — Dementia free at baseline
Raj 2017 [59] CHAP 2 588 70.4 (5.0) 11.9 (3.2) 37 African-American UTAI 12 Dementia free at baseline
IIDP 1 178 75.5 (5.5) 11.0 (2.9) 34 UTAI 15
ROS/MAP 85 70.5 (7.6) 15.4 (3.4) 16 UTAI 19
MARS 113 76.9 (5.1) 14.8 (4.1) 39 UTAI 17
Reynolds 2013 [66] SATSA 1,609 72.3 (50.1–93)* — 42.3 Swedish 7.8 (0–17.8)* Dementia free at baseline
OCTO-Twin GENDER
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Savage 2018 [38] UKBB, Cogent, GENR, 269 867 52.87 — 46.26 Caucasian — —
S4S, TEDS, DTR, IMAGEN,
BLTS, NESCOG, GfG, FHS,
STR, HRS/HI IQ, RS, STSA
Shulman 2010 [91] ROS 414 87.1 (6.9) 16.5 (3.6) 38.9 United States — Dementia free at baseline;
98 incident MCI;
185 incident dementia
MAP
Sneikers 2017 [60] UKBB, GENR, TEDS, ALSPAC, 78 308 44.4 — — Caucasian — —
QIMR, RAINE, HU, ERF,
STR, LBC1921, LBC1936
Sweet 2012 [53] CHS 1 831 71.7 (4.7) 39.9% w/ some college 37.5 Caucasian UPTAI 9 Dementia free at baseline
Thambisetty 2013 [51] BLSA 599 67.5 (7.5) 16.5 (2.5) 57.1 22.4% African-American 6.6 (4.6) CN
95 75.9 (7.1) 16.2 (3.1) 56.8 77.6% Caucasian 5.4 (4.2) MCI/AD converters
Verhaaren 2013 [48] Rotterdam Study 5 171 66.2 (11.2) 12.8% primary education only 43.6 Dutch — Dementia free at baseline
Vivot 2015 [46] 3C 4 931 74.0 (70.0–78.2)† 36%>9 years 38 French UTAI 10 Dementia free at baseline
Zhang 2014 [49] HRS 5 808 64.0 (7.3) ≥college 21.8% 42.8 Caucasian UTAI 13 —
*Median (range); †Median (IQR); UTAI, Up to and Including.
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Search strategy141
A PubMed database search (see Supplementary142
Material) included papers published between Jan-143
uary 2009 (the publication year of the first GWAS144
to identify non-APOE genome-wide significant SNPs145
for LOAD) and April 2018 (inclusive). Articles were146
restricted to human studies published in English. Ref-147
erence lists of all articles selected for data extraction148
were screened for additional articles.149
Inclusion and exclusion criteria150
Studies were included in the review if they met151
the following inclusion criteria: 1) included genetic152
data from non-APOE genome-wide significant risk153
loci for LOAD (ABCA7, BIN1, CD2AP, CD33,154
CLU, CR1, EPHA1, MS4A4A, MS4A4E, MS4A6A,155
PICALM, HLA-DRB, PTK2B, SORL1, SLC24A4,156
RIN3, INPP5D,MEF2C, NME8, ZCWPW1, CELF1,157
FERMT2, CASS4, HBEGF, ECHDC3, SPPL2A, and158
SCIMP) or a LOAD genetic risk score (GRS); 2)159
included at least one test measuring cognitive per-160
formance; 3) the publication was in English; 4) it161
was either cross-sectional or longitudinal. Articles162
were excluded if they were: 1) case only studies, case163
reports or review articles; 2) animal studies; or 3)164
conducted in a clinical population.165
Abstract screening and article selection166
Article citations and abstracts were imported into167
Covidence [35], rated against the selection crite-168
ria, and nominated independently for inclusion in169
full-text screening by SJA and GPM. Subsequently,170
full-text articles were assessed for inclusion in the171
final review. When the two reviewers differed, the172
article was discussed until a consensus was reached.173
Inter-rater reliability was assessed by calculating174
a two-way consistency average-measures interclass175
correlation coefficient (ICC).176
Data extraction177
For articles included in the systematic review, the178
following variables were extracted: 1) study design179
(i.e., longitudinal or cross-sectional; candidate SNPs,180
gene-based or GWAS analysis; statistical test); 2)181
sample characteristics (i.e., sample size, age, edu-182
cation, gender, ethnicity/population, follow-up, and183
cognitive status); 3) genetic variants examined; 4)184
cognitive tests examined; and 5) reported associa-185
tions (i.e., non-significant result, positive association, 186
negative association). Given the heterogeneity in the 187
measures with which the reviewed articles assessed 188
cognitive performance, all the cognitive tests were 189
coded within conventional cognitive domains [33] 190
(Supplementary Table 2). These domains are based 191
on the typical taxonomy found in the neuropsycho- 192
logical literature and were used in pervious previous 193
meta-analyses on the effect of APOE on cognitive 194
performance [33, 36]. Cognitive domains included: 195
attention (AT), episodic memory (EM), executive 196
function (EF), global cognition (GC), perceptual 197
speed (PS), working memory (WM), verbal ability 198
(VA), and visuospatial skill (VS). Two general cog- 199
nition clusters were included: fluid cognition (Gf) and 200
crystallized cognition (Gc). Study quality was eval- 201
uated using the 11-item Quality of Genetic Studies 202
(Q-Genie) Tool [37] (Supplementary Material). 203
Novel AD loci 204
The initial screen did not include the 16 novel 205
loci identified by Marioni et al. [28], Janssen et al. 206
[29], and Kunkle et al. [30] (ADAM10, KAT8, ACE, 207
ADAMTS4, HESX1, CLNK, CNTAP2, APH1B, ABI3, 208
ALPK2, ACO74212.3, OARD1, TREM2, IQCK, 209
WWOX, and ADAMTS1) as these studies were pub- 210
lished after the database search and article screening 211
were conducted. As such, for the loci reported in these 212
studies we limited our search to articles citing either 213
the BioRxiv pre-print article or the published arti- 214
cle as of March 2019. Additionally, where GWAS 215
summary statistics were available for cognitive phe- 216
notypes, we extracted the reported associations for 217
these loci. 218
RESULTS 219
Systematic literature search 220
The PubMed search identified 2,446 references 221
and follow-up screening of reference lists identi- 222
fied two additional articles. 2,395 references were 223
removed based on the inclusion/exclusion criteria. 224
Seventy-one full-text articles were reviewed, 21 were 225
excluded as follows: 1) fifteen due to selected AD 226
risk loci not reported, 2) one was an updated anal- 227
ysis of a previous study, 3) two because summary 228
statistics were not made publicly available, 4) three 229
as the study was conducted in adolescents. Forty- 230
nine articles were included in the systematic review 231
(Supplementary Figure 1). 232
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Table 2
Description of the Methods used for each study
Study Study Design Genetic risk Score Gene Symbols Cognitive Domains Statistical Test
Andrews 2017 [41] Longitudinal, candidate
SNPs
Unweighted & weighted
GRS w/ & w/o APOE
ABCA7, BIN1, CD2AP, CD33,
CLU, CR1, EPHA1, MS4A4A,
MS4A4E, MS4A6A, PICALM,
HLA-DRB5, PTK2B, SORL1,
SLC24A4-RIN3, INPP5D,
MEF2C, NME8, ZCWPW1,
CLEF1, FERMT2, CASS4
EM, EF, VA, PS Linear Mixed Effects
Models
Barral 2012 [90] Cross-sectional, candidate
SNPs
— BIN1, CLU, CR1, PICALM EM Logistic Regression
Bressler 2017 [44] Longitudinal, Candidate
SNPs
Unweighted GRS w/
APOE
ABCA7, BIN1, CASS4, CD2AP,
CD33, CELF1, CLU, CR1,
EPHA1, FERMT2, HLA-DRB1,
INPP5D, MEF2C, MS4A4E,
NME8, PICALM, PTK2B,
SLC24A4, SORL1, ZCWPW1
EM, PS, VA General Linear Models
Carrasquillo 2015 [42] Longitudinal, candidate
SNPs
Weighted GRS w/ & w/o
APOE
ABCA7, BIN1, CD2AP, CD33,
CLU, CR1, EPHA1, MS4A6A,
PICALM
EM Linear Mixed Effects
Models
Chibnik 2011 [57] Longitudinal, candidate
SNPs
— CLU, CR1, PICALM EM, GC, WM, VA, PS,
VS cognitive
composites
Linear Mixed Effects
Models
Christoforou 2014 [69] Cross-sectional, GWAGS — ABCA7, CLU, BIN1, CD2AP,
CD33, CR1, EPHA1, MS4A4A,
MS4A6A, MS4A4E, PICALM,
HLA-DRB5, PTK2B, SORL1,
SLC24A4, RIN3, INPP5D,
MEF2C, ZCWPW1, FERMT2,
CASS4, HBEFG, ECHDC3,
SCIMP, SPPL2A, ADAM10,
KAT8, ACE, ADAMTS4, HESX1,
CLNK, CNTAP2, APH1B, ABI3,
ALPK2, OARD1, TREM2, IQCK,
WWOX, ADAMTS1
Gf, Gc Gene - PLINK
permutation-based tests
Darst 2017 [68] Longitudinal, candidate
SNPs
Weighted pathway
specific GRS w/ & w/o
APOE
ABCA7, BIN1, CD2AP, CLU, CR1,
EPHA1, MS4A6A, PICALM,
HLA-DRB1, PTK2B, SORL1,
SLC24A4, INPP5D, NME8,
ZCWPW1, CLEF1, FERMT2,
CASS4, MEF2C
EM, WM, PS/EF factor
scores
Linear Mixed Effects
Models
Davies 2014 [68] Longitudinal, GWAS — ABCA7, BIN1, CD2AP, CD33,
CLU, CR1, MS4A6A, PICALM
Gf Growth Curve Models
(continued)
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(continued)
Study Study Design Genetic risk Score Gene Symbols Cognitive Domains Statistical Test
Davies 2015 [61] Cross-sectional,
gene-based
— ABCA7, BIN1, CD2AP, CD33,
CLU, CR1, EPHA1, MS4A6A,
PICALM, HLA-DRB1,
HLA-DRB5, PTK2B, SORL1,
SLC24A4, RIN3, INPP5D,
MEF2C, ZCWPW1, FERMT2,
CASS4
Gf
Davies 2016 [58] Cross-sectional, GWAS — ABCA7, BIN1, CASS4, CD2AP,
CD33, CELF1, CLU, CR1,
EPHA1, FERMT2,
HLA-DRB5–HLA-DRB1,
INPP5D, MEF2C, MS4A6A,
NME8, PICALM, PTK2B,
SLC24A4-RIN3, SORL1,
ZCWPW1
EF, PS, EM
Davies 2018 [39] Cross-sectional, GWAS;
GWAGS
— ABCA7, BIN1, CASS4, CD2AP,
CELF1, CD33, CLU, CR1,
EPHA1, FERMT2, HLA-DRB5,
INPP5D, MS4A6A, MS4A4A,
MS4A4E, MEF2C, NME8,
PICALM, PTK2B, SORL1,
SLC24A4-RIN3, ZCWPW1,
HBEGF, SPPL2A, ECHDC3,
SCIMP, ADAM10, KAT8, ACE,
ADAMTS4, HESX1, CLNK,
CNTAP2, APH1B, ABI3, ALPK2,
OARD1, TREM2, IQCK, WWOX,
ADAMTS1, AC074212.3
GC Linear Regression
Debette 2015 [56] Cross-sectional, GWAS Weighted GRS w/ & w/o
APOE
CLU, EPHA1, CD2AP, PICALM,
MS4A6A, BIN1, CD33, CR1,
ABCA7, PTK2B, SORL1,
SLC24A4, INPP5D, MEF2C,
NME8, ZCWPW1, CELF1,
FERMT2, CASS4
EM Linear Regression
DeJager 2012 [78] Longitudinal, GWAS Weighted GRS w/o APOE CR1, PICALM, CLU, BIN1,
ABCA7, MS4A, CD2AP, EPHA1,
CD33
GC cognitive composite Linear Mixed Effects
Models: Modelled
Change Linear
regression for GWAS
Engelman 2013 [43] Longitudinal, candidate
SNPs
— ABCA7, BIN1, CD2AP, CD33,
CLU, CR1, EPHA1, MS4A,
PICALM
EM, WM, EM factor
scores
Linear Mixed Models
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Ferencz 2014 [70] Cross-sectional, candidate
SNPs
Unweighted GRS PICALM, CLU, BIN1 EM, PS, VA ANCOVA
Ge 2018 [75] Longitudinal Weighted PGRS w/
APOE
— EM, EF Linear Mixed Effects
Models
Gui 2014 [88] Longitudinal, candidate
SNPs
Weighted GRS w/ APOE BIN1, CD2AP, CLU, SORL1,
PICALM, MS4A6A, MS4A4E,
ABCA7, CD33
EM Maximum Likelihood
multiple linear
regression
Hagenaars 2016 [95] Cross-sectional PGRS — EF, PS, EM Linear Regression
Hagenaars 2017 [50] Cross-sectional; GWAS;
GWAGS
— ABCA7, BIN1, CASS4, CD2AP,
CD33, CELF1, CLU, CR1,
EPHA1, FERMT2, HLA-DRB1,
MEF2C, MS4A4A, MS4A4E,
MS4A6A, NME8, PICALM,
PTK2B, SLC24A4, ZCWPW1,
HBEFG, ECHDC3, SCIMP,
SPPL2A, ADAM10, KAT8, ACE,
ADAMTS4, HESX1, CLNK,
CNTAP2, APH1B, ABI3, ALPK2,
OARD1, TREM2, IQCK, WWOX,
ADAMTS1
AT, EF Linear Regression
Hamilton 2011 [47] Longitudinal, candidate
SNPs
— BIN1, CLU, CR1, PICALM GC, VA, EF, EM ANOVA
Harris 2014 [96] Longitudinal PGRS — Gf, Gc, PS, EM Partial Correlations
Hill 2018 [40] Cross-sectional, GWAS;
GWAGS
— ABCA7, MEF2C, HBEGF, CELF1,
ZCWPW1, SPPL2A, HLA-DRB1,
SLC24A4, HLA-DRB5, SORL1,
PICALM, CR1, RIN3, ECHDC3,
FERMT2, SCIMP, INPP5D,
BIN1, CLU, PTK2B, CD2AP,
MS4A4E, CD33, CASS4,
MS4A4A, EPHA1, MS4A6A,
NME8, ADAM10, KAT8, ACE,
ADAMTS4, HESX1, CLNK,
CNTAP2, APH1B, ABI3, ALPK2,
OARD1, TREM2, IQCK, WWOX,
ADAMTS1, AC074212.3
GC Multi-Trait Analysis of
GWAS (MTAG)
Houlihan 2009 [62] Cross-sectional, candidate
SNPs
— SORL1 GC, EM, WM, EF, VS,
VA, PS
Linear Regression
Keenan 2012 [94] Longitudinal, candidate
SNPs
— CR1 EM cognitive composite Linear Mixed Effects
Models
(continued)
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(continued)
Study Study Design Genetic risk Score Gene Symbols Cognitive Domains Statistical Test
Liang 2015 [97] Cross-sectional, candidate
SNPs
— SORL1 GC, EM, EM, VS, VA,
PS, EF
MANOVA
Liao 2014 [87] Cross-sectional, candidate
SNPs
— ABCA7 GC ANOVA
Liebers 2016 [73] Longitudinal PGRS — GC, AT, EM Linear Mixed Effects
Models
Li 2017 [64] Cross-sectional, candidate
SNPs
— SORL1 GC, EM, VS, VA, PS, EF GLM
Liu 2009 [65] Cross-sectional, candidate
SNPs
— SORL1 EM, EF, GC cognitive
composites
GLM
Liu 2014 [67] Longitudinal, candidate
SNPs
— NME8 GC, EM ANOVA
Marden 2016 [71] Longitudinal Weighted GRS w/ & w/o
APOE
BIN1, CLU, ABCA7, CR1,
PICALM, MS4A6A, CD33,
CD2AP, EPHA1, HLA, PTK2B,
SORL1, SLC24A4, INPP5D,
MEF2C, NME8, ZCWPW1,
CELF1, FERMT1, CASS4
EM Linear regression
Marioni 2017 [74] Cross-sectional PGRS — PS, EM Linear Mixed Effects
Models
McFall 2016 [92] Longitudinal, candidate
SNPs
— CLU EF factor scores Growth curve models
Mengel-From 2011 [54] Cross-sectional, candidate
SNPs
— CLU, PICALM, CR1 GC Linear Regression
Mengel-From 2013 [55] Longitudinal, candidate
SNPs
— CLU GC Linear Mixed Effects
Models
Mormino 2016 [72] Longitudinal PGRS — EM, EF factor scores Linear Mixed Effects
Models
Nettiksimmons 2016 [45] Longitudinal, candidate
SNPs, gene-based
— ABCA7, BIN1, CASS4, CD2AP,
CD33, CELF1, CLU, CR1,
EPHA1, FERMT2, HLA,
INPP5D, MEF2C, MS4A, NME8,
PICALM, PTK2B, SLC24A4,
SORL1, ZCWPW1
GC Linear Mixed Effects
Models
Pedzara 2014 [52] Cross-sectional, candidate
SNPs
— CLU, CR1, PICALM EM Linear Regression
Qiu 2016 [93] Cross-sectional, candidate
SNP
— CLU GC, PS, VA t-test
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Raj 2017 [59] Longitudinal, GWAS — ABCA7, MS4A6A, CASS4,
INPP5D, SORL1
GC cognitive composite Linear Mixed Effects
Models
Reynolds 2013 [66] Longitudinal, candidate
SNPs
— SORL1 VA, EM, PS, WM Linear Mixed Effects
Models
Savage 2018 [38] Cross-sectional, GWAS;
GWAGS
— MEF2C, HBEGF, SPPL2A,
SLC24A4, CR1, CELF1, RIN3,
ZCWPW1, ECHDC3, CLU,
ABCA7, PICALM, SORL1,
BIN1, INPP5D, EPHA1, CASS4,
MS4A4E, SCIMP, MS4A6A,
CD2AP, MS4A4A, FERMT2,
PTK2B, CD33, NME8, ADAM10,
KAT8, ACE, ADAMTS4, HESX1,
CLNK, CNTAP2, APH1B, ABI3,
ALPK2, OARD1, TREM2, IQCK,
WWOX, ADAMTS1, AC074212.3
GC Gene test
Shulman 2010 [91] Cross-sectional, candidate
SNPs
— SORL1, CD33 EM, VA, WM, PS, VS
cognitive composites
Linear Regression
Sneikers 2017 [60] Cross-sectional, GWAS;
GWAGS
— MEF2C, HBEGF, CELF1,
ZCWPW1, MS4A4E, MS4A6A,
SLC24A4, PICALM, MS4A4A,
SCIMP, CD2AP, HLA-DRB1,
SORL1, PTK2B, CD33, NME8,
CR1, HLA-DRB5, BIN1,
SPPL2A, ECHDC3, EPHA1,
CLU, CASS4, ABCA7, RIN3,
FERMT2, ADAM10, KAT8, ACE,
ADAMTS4, HESX1, CLNK,
CNTAP2, APH1B, ABI3, ALPK2,
OARD1, TREM2, IQCK, WWOX,
ADAMTS1, AC074212.3
GC Regression
Sweet 2012 [53] Longitudinal, candidate
SNPs
— CLU, CR1, PICALM GC, AT Bayesian Modelling
Thambisetty 2013 [51] Longitudinal, candidate
SNPs
— CLU EM Linear Mixed Effects
Models
Verhaaren 2013 [48] Cross-sectional, candidate
SNPs
Weighted GRS w/ & w/o
APOE
CLU, PICALM, BIN1, CR1,
ABCA7, MS4A6A, MS4A4E,
CD2AP, EPHA1, CD33
GC, EM, EF, PS cognitive
composites
Linear Regression
Vivot 2015 [46] Longitudinal, candidate
SNPs
Weighted GRS w/ & w/o
APOE
CR1, CLU, BIN1, PICALM,
ABCA7, MS4A4E, CD33,
MS4A6A, CD2AP
GC, VA, GC, PS, EM non-linear mixed models
with latent processes
Zhang 2014 [49] Longitudinal, GWAS — PICALM, CD2AP, CR1, EPHA1,
MS4A, CLU, CD33, ABCA7,
BIN1
GC Linear Mixed Effects
Models
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For each study we report study characteristics233
(Table 1), study design (Table 2), individual cog-234
nitive tests and the respective cognitive domains235
tested (Supplementary Table 2), and individual SNPs236
genotyped (Supplementary Table 3). Of the forty-237
nine studies, 23 employed a cross-sectional design238
and 26 a longitudinal design. 29 selected SNPs239
based on a candidate gene approach, 7 employed240
gene-based analyses, 6 reported AD risk loci as a sec-241
ondary outcome in GWAS, and 17 included a GRS,242
with 8 studies only using a GRS. Episodic mem-243
ory (n= 31, 63.27%) and global cognition (n= 23,244
46.94%) were the most commonly assessed cognitive245
measures.246
The overall average quality rating was ‘good’,247
with four studies obtaining a ‘moderate’ score. The248
distribution and mean rating for each item and the249
average score per study are presented in Supplemen-250
tary Figures 2 and 3. The ICC was in the excellent251
range (ICC = 0.88 95%CI: 0.79 - 0.93), indicating252
that reviewers had a high degree of agreement in the253
overall quality of the included studies.254
Association of AD genetic risk loci with cognitive255
performance and change256
In the following narrative, we report all gene-257
cognition associations that are statistically significant258
(p< 0.05) (Figs. 1 and 3). However, it should be259
noted that the majority (84.3%) of the reported260
associations were non-significant (Supplementary261
Table 4). The number of studies investigating the262
association of each LOAD loci with cognitive func-263
tion and the number of studies reporting at least264
one significant association for each gene-cognitive265
domain combination is reported in Supplementary266
Table 4. Across cognitive domains/clusters, GC had267
the highest proportion of reported significant associ-268
ations (30.2%, 77/255) followed by VS (30%, 3/10),269
VA (14.29%, 16/112), EM (14.29%, 32/224), AT270
(13.33%, 6/45), EF (11.86%, 14/118), PS (11.79%,271
23/195), Gf (7.46%, 5/67), WM (4.05%, 3/74), and272
Gc (0%, 0/38). The largest studies to report an asso-273
ciation between the AD risk loci and GC, were two274
GWAS meta-analyses inclusive of the UK Biobank275
(n= 269,867 and 300,486) [38, 39] and a multi-trait276
analysis of intelligence and educational attainment277
(n= 248,482) [40]. Davies et al. [39] found 18 loci278
associated with GC (MEF2C, HBEGF, SPPL2A,279
IQCK, ABI3, FERMT2, CELF1, CR1, CNTNAP2,280
SLC24A4, AC074212.3, CLU, ABCA7, ADAM10,281
PTK2B, CD2AP, CLNK, and WWOX), of which only282
MEF2C, HBEGF, and SPPL2A were genome-wide 283
significant. Savage et al. found 11 loci to be asso- 284
ciated with GC (MEF2C, HBEGF, SPPL2A, CR1, 285
SLC24A4, OARD1, CNTNAP2, WWOX, ZCWPW1, 286
CELF1, and ABCA7), of which MEF2C, HBEGF, 287
and SPPL2Awere also genome-wide significant [38]. 288
Finally, Hill et al. [40] identified 13 loci associated 289
with global cognition (MEF2C, HBEGF, CELF1, 290
ZCWPW1, SPPL2A, WWOX, HLA-DRB1, SLC24A4, 291
ADAMTS4, ALPK2, ACE, SORL1, and PICALM), of 292
whichMEF2C,HBEGF, CELF1, and ZCWPW1were 293
genome wide significant. 294
ABCA7 295
rs3764650(G) was associated with worse base- 296
line performance and slower decline in EM [41]. 297
In a second study, rs3764650(C) was associated 298
with faster decline in EM in cognitively normal 299
participants who converted to mild cognitive impair- 300
ment (MCI)/Alzheimer’s disease (AD), but not in 301
participants who remained cognitively normal [42]. 302
Additionally, rs3752246(G) was associated with 303
worse performance in EM and WM at baseline 304
[43], whereas rs4147929(A) was associated with 305
better baseline EM [44] and EF [39] performance. 306
Change in GC was associated with rs115550680(G) 307
in African-Americans and with the ABCA7 gene- 308
region in a female only and a male only cohort [45]. 309
BIN1 310
rs744373(G) was associated with worse baseline 311
EM performance [41] and a faster rate of decline 312
in global cognition [46]. In univariate (7 SNPs) 313
and haplotype analyses (two 3-SNP windows), sig- 314
nificant associations were observed for cognitive 315
performance in EM, EF, VA, and GC [47]. The BIN1 316
gene region was associated with change in GC in 317
females [45]. 318
CD2AP 319
rs9349407(C) and rs9296559(G) were associated 320
with worse EM performance and a faster rate of 321
decline in GC respectively [48, 49]. The CD2AP gene 322
region was also associated with performance in AT 323
[50] and PS [39]. 324
CD33 325
rs3865444(C) was associated with worse baseline 326
performance in EF [48], and in African-Americans 327
rs3865444(A) was associated with worse baseline 328
performance in VA [44]. The CD33 gene region and 329
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rs3865444 were associated with change in GC in330
females [45].331
CLU332
rs11136000(C) was associated with faster decline333
in WM [41] and EM in participants who converted334
to MCI/AD, but not in participants who remained335
cognitively normal [51]. rs11136000(C) was also336
associated with better performance in EM in a337
combined cohort of case/controls, but not in non-338
demented subjects only [52]. In a follow-up study,339
rs11136000(G) was associated with worse baseline340
performance in EM [42]. rs11136000(T) minor allele341
was associated faster decline in GC [53]. Mengel-342
From et al. [54, 55] investigated the association of343
four separate SNPs in the CLU locus with cognitive344
function. They reported that rs11136000(T) was asso-345
ciated with better baseline GC, rs9331888(G) and346
rs9331908(T) were associated with slower decline347
and rs11136000(T) and rs1532278(T) were associ-348
ated with faster decline [54, 55]. Bressler et al. [44]349
observed that rs9331896(C) was associated with bet-350
ter baseline performance in EM and a reduced rate351
of decline in PS. rs2279590(A) was associated with352
worse performance in EM [56] and two separate 3-353
SNP haplotypes were significantly associated with354
baseline performance in EM and VA [47].355
CR1356
rs3818361(T) was associated with faster decline357
in AT [53], while rs3818361(A) was associated with358
baseline performance in GC and faster decline in359
VA [47, 46]. Additionally, in African-Americans360
rs3818361(A) was associated with worse perfor-361
mance in EM in both a combined case/control362
cohort and non-demented control only subjects [52].363
rs6656401(A) was associated with improved base-364
line performance in PS in African-American [44] and365
with faster decline in EM, semantic memory, PS, VS,366
and GC [47, 57]. Finally, a 3-SNP haplotype and367
2-SNP haplotype was associated with VA and GC,368
respectively [47]. The CR1 gene region was associ-369
ated with change in GC in females [45], PS [39], and370
GC [38].371
EPHA1372
rs11767557(C) and rs11767557(T) were associ-373
ated with worse EM performance [48] and faster374
decline in WM, respectively [41]. Additionally,375
rs11767557(A) was associated with a faster rate376
of decline in EM in participants who converted to377
MCI/AD, but not in participants who remained cog- 378
nitively normal [42]. 379
MS4A 380
MS4A6A-rs983392(G) was associated with worse 381
EM performance [58] and in African-Americans with 382
change in GC [59]. MS4A4E-rs670139(T) was asso- 383
ciated with better baseline WM [41] and slower 384
decline in EM [44]. The MS4A4E and MS4A6A gene 385
regions were associated with GC [60]. 386
PICALM 387
rs3851179(A) and rs3851179(G) were associated 388
with better baseline GC [54] and faster decline in 389
GC respectively [49]. rs7110631(G) was associated 390
with faster decline in EM, VA, and GC [57], while 391
rs541458(C) was associated with an earlier age at 392
midpoint in decline in a non-linear trajectory of GC 393
[53]. In univariate analysis 4 SNPs (rs10501604, 394
rs10792821, rs11234532, rs10501608) were associ- 395
ated with EF, while in haplotype analyses 12 3-SNP 396
windows were associated with EF [47]. ThePICALM 397
gene region was associated with Gf performance [61] 398
GC in a multi-trait analysis of intelligence and edu- 399
cational attainment [40], and with change in GC in 400
males [45]. 401
SORL1 402
rs3824968(A) was associated with worse EM 403
performance at age 70, before and after adjust- 404
ing for childhood IQ at age 11 [62]. In Chinese 405
participants, rs2070045(T) was associated with PS 406
performance [63] and rs1699102(T) was associated 407
with faster decline in EM and PS [64]. rs11218343(T) 408
was associated with worse PS at baseline [41]. In 409
African-Americans, rs11218343(C) was associated 410
with change in GC [59]. The SOLR1 gene region was 411
associated with change in GC in males [45] and with 412
GC in a multi-trait analysis of intelligence and educa- 413
tional attainment [40]. In a Dutch population-based 414
study, rs668387(T), rs689021(A), and rs641120(T) 415
were associated with worse EM performance, but bet- 416
ter EM and GC performance [65]. A further three 417
SNPs (rs3824968(T), rs2282649(T), rs1010159(C)) 418
were associated with better performance in EF in the 419
family based study [65]. In three Swedish based pop- 420
ulation cohorts, five SNPs (rs11600875, rs753780, 421
rs7105365, rs11820794, rs2070045) were variously 422
associated with performance in EM, VA, and 423
VS [66]. 424
The HLA gene region was associated with change 425
in GC in a female only and male only cohort 426
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[45]. The PTK2B gene region was associated with427
change in GC in males [45]. The SLC24A4 gene428
region was associated with Gf performance [61]429
GC in a multi-trait analysis of intelligence and430
educational attainment [40] and in a meta-analysis431
inclusive of the UKBB [38], and change in GC432
[45]. INPP5D-rs35349669(T) was associated with433
better baseline VA [44], slower decline in EM, and434
faster decline in PS [41]. In African-Americans, the435
INPP5D-rs4585024(A) minor allele was associated436
with change in GC [59]. MEF2C-rs190982(A) was437
associated with decreased EF performance in the438
UKBB, though it was non-significant in an earlier,439
smaller, analysis [39]. The MEF2C gene region was440
associated with GC in a multi-trait analysis of intelli-441
gence and educational attainment [40], GC in two442
large meta-analyses inclusive of the UK Biobank443
[38], Gf performance [61], and change in GC in males444
[45]. NME8-rs12155159(G) was associated with445
slower decline in VA [44] and NME8-rs2718058(G)446
was associated with worse baseline performance and447
faster decline in GC [67]. ZCWPW1-rs1476679(T)448
was associated with slower decline in PS [41], while449
in African-Americans ZCWPW1-rs1476679(C) was450
associated with faster decline in EM [44]. For451
CELF1, rs6485758(A) was associated with better452
baseline performance in EM, VA, and PS [44],453
while rs10838725(C) and rs7933019(C) were asso-454
ciated with better baseline EF performance [58]455
and a slower decline in EM [41], respectively.456
rs10838725(T) was associated with decreased EF457
performance [39]. The CELF1 gene region was asso-458
ciated with change in GC in females [45], GC in a459
multi-trait analysis of intelligence and educational460
attainment [40], GC in three large meta-analyses461
inclusive of the UK Biobank [38, 39], and with462
PS [39]. FERMT2-rs17125944(C) with better EM463
performance [68], worse baseline VA [44], and accel-464
erated decline in PS [41]. CASS4-rs927174(C) was465
associated with change in GC in African-Americans466
[59].467
For the novel loci identified by Yiu et al., Marioni468
et al., Janssen et al. and Kunkle et al., there were469
no articles that reported associations of these loci470
with cognitive performance. Our initial search identi-471
fied 6 GWAS where summary statistics were publicly472
available and for which we could extract the reported473
associations. The HBEGF and SPPL2A gene regions474
were associated with GC in a multi-trait analysis of475
intelligence and educational attainment [40], and in476
two large meta-analyses inclusive of the UK Biobank477
[38,39]. The ADAM10 gene region was associated478
with GC and ADAM10-rs889555(T) was associated 479
with worse GC performance [39]. The KAT8 gene 480
region was associated with AT and EF [50]. The 481
ACE gene region was associated with EF [50], PS 482
[39] performance in the UK Biobank, and GC [40]. 483
The CLNK gene region was associated with PS and 484
GC, while CLNK-rs6448453(A) was associated with 485
worse and better EF and PS performance, respectively 486
[39]. The CNTNAP2 gene region was associated with 487
GC in two large meta-analyses inclusive of the UK 488
Biobank [38, 39] and general fluid intelligence [69]. 489
The APH1B and HESX1 gene regions were associ- 490
ated with PS in the UK Biobank [39]. TheALPK2 and 491
ADAMTS4 gene regions were associated with GC in 492
a multi-trait analysis of intelligence and educational 493
attainment [40]. ADAMTS1-rs2830500(A) was asso- 494
ciated with worse EF and better PS [39]. The ABI3 495
gene region was associated with GC [39, 60] and gF 496
[69] while ABI3-rs28394864(A) was associated with 497
better PS. The ACO74212.3 gene region was associ- 498
ated with GC and ACO74212.3-rs76320948(T) was 499
associated with worse GC [39, 60] and better PS [39]. 500
TheOARD1 gene region was associated with AT [50] 501
and GC [38], while rs114812713(C) was associated 502
with better PS [39]. IQCK-rs7185636(T) was associ- 503
ated with worse GC performance [39]. The WWOX 504
gene region was associated with GC [38–40] while 505
WWOX-rs62039712(A) was associated with worse 506
PS [39]. 507
Association of AD GRS with cognitive 508
performance 509
We found 14 studies that investigated the cumula- 510
tive effect of AD risk loci on cognitive performance. 511
Three studies investigated the effect of an unweighted 512
GRS on cognitive performance. An unweighted GRS 513
composed of PICALM, BIN1, and CLU, was associ- 514
ated with reduced EM performance [70]. In contrast, 515
an unweighted GRS composed of the IGAP risk loci 516
was not associated with either both cognitive per- 517
formance or cognitive decline [38, 41]. Weighted 518
GRSs that include APOE have shown more consis- 519
tent results. GRS composed of SNPs identified in the 520
initial GWAS have been associated with worse cog- 521
nitive performance in EM [42, 46, 48], EF [48], VA 522
[46], PS [46, 48], and GC [46, 48]. Studies that have 523
used a GRS including the IGAP LOAD risk loci have 524
also reported associations with worse performance in 525
EM [41, 56, 71] and PS [41]. However, these associa- 526
tions largely reflect the effect ofAPOE as the majority 527
are not statistically significant after the exclusion of 528
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APOE. Pathway specific risk scores for A clearance,529
cholesterol metabolism, and immune response were530
also constructed but were non-significant [68].531
Five studies have utilized a GRS approach,532
whereby a GRS is calculated based on all genome-533
wide significant SNPs, plus all nominally associated534
variants at a given significance level (PT). Two GRS535
(PT = 0.01) were associated with worse baseline EM536
and faster decline on EF and [72] and with worse EM537
and GC and faster decline in GC [73]. A third GRS538
composed of all LOAD-related SNPs (PT = 1) except539
for those within 500 kb of APOE was associated with540
worse baseline EM [74]. One study found that GRS541
across a range PT ranging from 1e-7 to 1e-2 was asso-542
ciated with faster EM and EF performance decline in543
A+, but not A- individuals [75].544
DISCUSSION545
This is the first systematic review to evaluate the546
role of non-APOE LOAD GWAS risk loci in cogni-547
tive decline. Based on a synthesis of data from 49548
published studies, the results between individual risk549
loci and specific cognitive domains were largely non-550
significant for both baseline/cross-sectional cognitive551
performance and for longitudinal cognitive change.552
Of the significant gene-cross-sectional/longitudinal553
cognition associations that were reported (n= 128),554
the majority (n= 96) were not reproduced; other555
reviewed studies reported non-significant associa-556
tions. Moreover, inconclusive patterns emerged for557
significant associations that were reproduced by one558
or more studies. Specifically, three reported signif-559
icant effects in the same direction, three reported560
significant associations, but with inconsistent direc-561
tions of effect, 12 were reproduced as significant by562
studies that did not report the direction of effect, and563
finally, 12 were reported as significant but no direc-564
tion of effect was reported. However, it should be565
noted, where significant associations were reported566
and reproduced, the majority of further replication567
studies reported non-significant associations results.568
Overall, global cognition was the most extensively569
examined cognitive domain, with 77/255 significant570
associations reported. This low rate of significance571
and the concomitant lack of reproducibility of sig-572
nificant associations were observed across all the573
cognitive domains.574
In contrast to univariate and gene-based analysis,575
we found more studies reporting consistent signif-576
icant results of genetic risk scores associated with577
episodic memory performance. GRS composed of 578
GWAS top hits and APOE were associated with 579
worse cognitive performance in episodic memory, 580
with 4/7 cross-sectional studies and 4/4 longitudinal 581
studies reporting significant associations. However, 582
these effects were largely driven by APOE, with 583
only 2/7 baseline associations and 1/4 longitudi- 584
nal associations retaining significance after APOE 585
was excluded from the GRS. GRS composed of 586
all nominally associated variants at a given signif- 587
icance level were also consistently associated with 588
worse episodic memory performance, with 5/6 of 589
the studies reporting significant associations. Given 590
these results, future studies should focus on the use 591
of GRS rather than individual variants, where the 592
effects are likely too small to be reliably detected 593
in a univariate analysis [76]. Furthermore, aggre- 594
gating risk variants based on biological function 595
may offer a more powerful approach to evaluat- 596
ing the association of genetic variants with specific 597
endophenotypes [68]. 598
Sample size/statistical power 599
A major limitation of the reported studies is small 600
sample sizes and consequently low statistical power. 601
In order to detect a genetic variant explaining 1% 602
of cognitive variance at 80% power, early analy- 603
ses suggested a sample size of 800–1,000 [77], but 604
more recent genome-wide associations analyses esti- 605
mate 10,000–15 000 is required [78]. Of the included 606
studies, 37/49 had a sample size greater than 1,000, 607
but only 9/49 studies had greater than 10,000. The 608
two largest GWAS of cognitive performance to date, 609
conducted as a meta-analysis of the UK Biobank 610
and other consortia (n= 300,486 [39] & n= 269,867 611
[38]), found three LOAD gene-regions reaching 612
genome-wide significance: MEF2C, HBEGF, and 613
SPPL2A. However, it should be noted that HBEGF 614
and SPPL2A were associated with dementia proxy 615
case/control status in the UK Biobank and in both 616
of these studies the majority of the samples (∼30%) 617
originated in the UKBB. The UK Biobank has two 618
limitations relevant to this review: it is limited to a 619
cross-sectional design and the cognitive assessments 620
used are brief non-standard tests that are suscep- 621
tible to floor/ceiling effects [79]. Future studies, 622
particularly longitudinal studies, should recruit larger 623
sample sizes, or alternately, greater efforts should be 624
made to harmonize data across studies to facilitate 625
meta-analysis. 626
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Phenotypic heterogeneity627
Phenotypic heterogeneity between studies due to628
the use of different cognitive tests can limit repli-629
cation [61]. While cognitive test results are highly630
correlated, some tests may lack the sensitivity to631
identify associations with small effect sizes, such632
as Mini-Mental State Examination (MMSE) [80],633
a commonly used GC test. MMSE was designed634
as a screening test for dementia and not a mea-635
sure of cognitive abilities. It therefore exhibits strong636
ceiling effects, limiting its ability to differentiate637
between medium and high cognitive performers [81].638
There was vast between-study variability in the spe-639
cific measures used to assess the different cognitive640
domains. Although most of the cognitive measures641
used were psychometrically sound, replication of642
genetic effects on a specific cognitive domain may643
have been tested using measures that differed in valid-644
ity, reliability, or sensitivity [82]. Additionally, when645
evaluating the effects of AD risk loci on cognitive646
aging a broad range of relevant cognitive domains647
should be assessed using multiple cognitive tests648
per domain. The construction of latent variables or649
composite scores offer several advantages over using650
single cognitive tests scores [83]. For example, latent651
variables use multiple indicators, rather than a single652
measure, thus representing a more compressive cog-653
nitive construct that by design reduces the impact of654
varying psychometric properties [84]. Alternatively,655
when examining cognition as an endophenotype of656
LOAD, a cognitive test battery focused on cognitive657
domains more directly affected pre-clinical AD, such658
as episodic memory, may be warranted. Given these659
findings, future studies should 1) focus on specific660
cognitive domains rather than global tests; 2) choose661
cognitive tests specifically for their sensitivity to mea-662
sure subtle cognitive differences; 3) use multiple tests663
to assess cognitive function of a single domain; and664
4) that are robust to test-retest effects.665
Sample characteristics666
Variation in sample characteristics such as age, sex,667
education, ethnicity, and medical comorbidities can668
limit replicability. In particular, inclusion/exclusion669
of individuals who develop dementia during a study670
may affect results. Of the studies included in this671
review, 26/49 were conducted in non-demented pop-672
ulations, 11/49 included participants with prevalent673
or incident dementia, while 12/49 studies did not674
report the cognitive status of its participants. The675
reported associations of LOAD risk loci in pop- 676
ulations that retain prevalent or incident cases of 677
cognitive impairment may be driven by pathologi- 678
cal cognitive decline [61, 85]. In contrast, in studies 679
that selectively exclude participants with a clinical 680
diagnosis of dementia, the inadvertent inclusion of 681
individuals in prodromal stages of dementia may 682
also drive the reported genetic effects [85]. Evi- 683
dence to suggest this effect has been reported in 684
studies that separately assessed associations in par- 685
ticipants who eventually converted to dementia and 686
those who remained cognitively normal for ABCA7, 687
EPHA1, and CLU [42, 51]. Similar effects have been 688
observed for APOE*4 carriers [85]. In cognitively 689
normal APOE*4 carriers, participants with a high 690
A PET levels experienced a faster rate of decline 691
then carriers with low A PET levels, suggesting 692
that cognitive decline observed in APOE*4 carriers 693
reflects the effect of APOE exacerbating A-related 694
decline rather than an APOE-independent effect [86]. 695
Accordingly, future studies should evaluate the asso- 696
ciation of LOAD risk loci with cognitive function 697
using neuroimaging or cerebrospinal fluid biomark- 698
ers to inform the classification of preclinical AD in 699
‘cognitively normal’ individuals. Furthermore, sen- 700
sitivity analysis should be conducted to evaluate if 701
the inclusion/exclusion of participants with MCI or 702
dementia drives potential association of genetic vari- 703
ants on cognitive function. 704
Limitations 705
There are several limitations to this review. First, 706
the heterogeneity in the methodologies (cognitive 707
tests, genetic polymorphisms, and study design) of 708
the included studies precluded performing a meta- 709
analysis, which would offer increased power to detect 710
associations and increased precision in the estimation 711
of the magnitude of the effect. Second, we empha- 712
size that we have reported significant associations 713
that were p< 0.05 but as such the number of ‘true’ 714
associations is probably smaller than the number 715
reported here due to multiple testing and undetected 716
publication bias. Third, the literature search used a 717
single database, PubMed, which could limit the sen- 718
sitivity of our search strategy. However, PubMed is 719
by far the most populated database for publications 720
for general medical and biomedical science offering 721
a higher likelihood of retrieval of relevant publica- 722
tions. In addition, we followed up reference lists 723
for all included studies and this retrieved less than 724
5% of studies eventually included, suggesting an 725
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acceptable sensitivity for the bibliographic database726
searches. Finally, while we adapted our search strat-727
egy from a published filter for detecting causation728
studies that favored sensitivity, it is possible that729
not all relevant studies were identified as our search730
strategy relied on the gene names or SNP identi-731
fiers being present within the title or abstract of a732
publication.733
Conclusion734
This is the first study to systematically evaluate735
the role of non-APOE LOAD risk loci with cog-736
nitive performance and decline. We found that the737
majority of associations between individual LOAD738
risk loci and cognitive function were non-significant,739
suggesting that current samples sizes are too small740
to detect individual risk loci effects on cognition. In741
contrast, consistent findings were observed for GRS,742
with increased LOAD genetic risk associated with743
deleterious effects on episodic memory performance744
and decline. Future research should focus on the use745
of GRS, recruitment of larger sample sizes or har-746
monization of findings across studies, and improved747
phenotyping of cognitive abilities. Consideration of748
these factors in future study design may allow for749
more reliable associations of LOAD-related genetic750
variants with ageing-related cognitive performance751
and change.752
ACKNOWLEDGMENTS753
SJA is funded by the Australian Research Council754
Centre of Excellence in Population Ageing Research,755
ARC grant CE1101029. KJA is funded by NHMRC756
Research Fellowship No. 1002560. RAD acknowl-757
edges funding from the National Institutes of Health758
(National Institute on Aging, R01 AG008235) and759
the Canadian Consortium on Neurodegeneration in760
Aging (with funding from the Canadian Institutes of761
Health Research and partners).762
Authors’ disclosures available online (https://763
www.j-alz.com/manuscript-disclosures/19-0342).764
SUPPLEMENTARY MATERIAL765
The supplementary material is available in the766
electronic version of this article: http://dx.doi.org/767
10.3233/JAD-190342.768
REFERENCES 769
[1] Salthouse TA (2009) When does age-related cognitive 770
decline begin? Neurobiol Aging 30, 507-514. 771
[2] Josefsson M, de Luna X, Pudas S, Nilsson L-G, Nyberg 772
L (2012) Genetic and lifestyle predictors of 15-year longi- 773
tudinal change in episodic memory. J Am Geriatr Soc 60, 774
2308-2312. 775
[3] Salthouse TA (2009) Decomposing age correlations on neu- 776
ropsychological and cognitive variables. J Int Neuropsychol 777
Soc 15, 650-661. 778
[4] Liverman CT, Yaffe K, Blazer DG (2015) Cognitive aging: 779
Progress in understanding and opportunities for action, 780
National Academies Press. 781
[5] Qiu C, Fratiglioni L (2015) A major role for cardiovascular 782
burden in age-related cognitive decline.Nat Rev Cardiol 12, 783
267-277. 784
[6] Feinkohl I, Price JF, Strachan MW, Frier BM (2015) The 785
impact of diabetes on cognitive decline: Potential vascular, 786
metabolic, and psychosocial risk factors. Alzheimers Res 787
Ther 7, 46. 788
[7] Lucin KM, Wyss-Coray T (2009) Immune activation in 789
brain aging and neurodegeneration: Too much or too little? 790
Neuron 64, 110-122. 791
[8] Masters CL, Bateman R, Blennow K, Rowe CC, Sperling 792
RA, Cummings JL (2015) Alzheimer’s disease.Nat Rev Dis 793
Primers 1, 15056. 794
[9] Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) 795
Stages of the pathologic process in Alzheimer disease: Age 796
categories from 1 to 100 years. J Neuropathol Exp Neurol 797
70, 960-969. 798
[10] Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens 799
P, Verhey FRJ, Visser PJ, Aalten P, Aarsland D, Alcolea D, 800
Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel 801
H, van Berckel BNM, Bibeau K, Blennow K, Brooks DJ, 802
van Buchem MA, Camus V, Cavedo E, Chen K, Chete- 803
lat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, 804
Fladby T, Fleisher AS, van der Flier WM, Ford L, Forster 805
S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, 806
Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatz- 807
ima O, Gomez-Tortosa E, Gordon MF, Grimmer T, Hampel 808
H, Hausner L, Hellwig S, Herukka S-K, Hildebrandt H, 809
Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla 810
R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Kohler 811
S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, 812
Landau SM, Lee DY, de Leon M, Lisetti V, Lleo A, Mad- 813
sen K, Maier W, Marcusson J, Mattsson N, de Mendonca 814
A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molin- 815
uevo JL, Mollergard HM, Morris JC, Mroczko B, Van der 816
Mussele S, Na DL, Newberg A, Nordberg A, Nordlund 817
A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters 818
O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IHGB, 819
Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, 820
Rodriguez-Rodriguez E, Roe CM, Rot U, Rowe CC, Ruther 821
E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schroder 822
J, Schutte C, Seo SW, Soetewey F, Soininen H, Spiru L, 823
Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Ver- 824
beek MM, Villemagne VL, Vos SJB, van Waalwijk van 825
Doorn LJC, Waldemar G, Wallin A, Wallin AK, Wiltfang 826
J, Wolk DA, Zboch M, Zetterberg H (2015) Prevalence of 827
cerebral amyloid pathology in persons without dementia: A 828
meta-analysis. JAMA 313, 1924-1938. 829
[11] Scholl M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi 830
M, Ossenkoppele R, Baker SL, Vogel JW, Faria J, Schwim- 831
mer HD, Rabinovici GD, Jagust WJ (2016) PET imaging 832
Un
co
rre
cte
d A
uth
or
 P
ro
of
22 S.J. Andrews et al. / Alzheimer’s Disease Genetics and Cognition
of tau deposition in the aging human brain. Neuron 89,833
971-982.834
[12] Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre835
J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp836
K, Marshall G, Albers M, Mauro S, Pepin L, Alverio J,837
Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson B,838
Gomez-Isla T, Hyman B, Vasdev N, Sperling R (2016) Tau839
positron emission tomographic imaging in aging and early840
Alzheimer disease. Ann Neurol 79, 110-119.841
[13] Hedden T, Oh H, Younger AP, Patel TA (2013) Meta-842
analysis of amyloid-cognition relations in cognitively843
normal older adults. Neurology 80, 1341-1348.844
[14] Boyle PA, Yu L, Wilson RS, Schneider JA, Bennett DA845
(2013) Relation of neuropathology with cognitive decline846
among older persons without dementia. Front Aging Neu-847
rosci 5, 50.848
[15] Petersen RC, Wiste HJ, Weigand SD, Rocca WA, Roberts849
RO, Mielke MM, Lowe VJ, Knopman DS, Pankratz VS,850
Machulda MM, Geda YE, Jack CR Jr (2016) Association851
of elevated amyloid levels with cognition and biomarkers852
in cognitively normal people from the community. JAMA853
Neurol 73, 85-92.854
[16] Hassenstab J, Chasse R, Grabow P, Benzinger TLS, Fagan855
AM, Xiong C, Jasielec M, Grant E, Morris JC (2016) Certi-856
fied normal: Alzheimer’s disease biomarkers and normative857
estimates of cognitive functioning. Neurobiol Aging 43, 23-858
33.859
[17] Yu L, Boyle PA, Leurgans S, Schneider JA, Bennett DA860
(2014) Disentangling the effects of age and APOE on neu-861
ropathology and late life cognitive decline.Neurobiol Aging862
35, 819-826.863
[18] Hohman TJ, Tommet D, Marks S, Contreras J, Jones R,864
Mungas D, Alzheimer’s Neuroimaging Initiative (2017)865
Evaluating Alzheimer disease biomarkers as mediators866
of age-related cognitive decline. Neurobiol Aging 58,867
120-128.868
[19] Ridge PG, Hoyt KB, Boehme K, Mukherjee S, Crane869
PK, Haines JL, Mayeux R, Farrer LA, Pericak-Vance MA,870
Schellenberg GD, Kauwe JSK (2016) Assessment of the871
genetic variance of late-onset Alzheimer’s disease. Neuro-872
biol Aging 41, 200.e13-20.873
[20] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE,874
Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-875
Vance MA (1993) Gene dose of apolipoprotein E type 4876
allele and the risk of Alzheimer’s disease in late onset fam-877
ilies. Science 261, 921-923.878
[21] Harold D, Abraham R, Hollingworth P, Sims R, Gerrish879
A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K,880
Williams A, Jones N, Thomas C, Stretton A, Morgan AR,881
Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C,882
Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K,883
Brown KS, Passmore PA, Craig D, McGuinness B, Todd884
S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG,885
Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W,886
Jessen F, Schurmann B, van den Bussche H, Heuser I, Korn-887
huber J, Wiltfang J, Dichgans M, Frolich L, Hampel H,888
Hull M, Rujescu D, Goate AM, Kauwe JSK, Cruchaga C,889
Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K,890
Engelborghs S, De yn PP, Van Broeckhoven C, Livingston891
G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas892
P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guer-893
reiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel894
K-H, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz895
VS, Younkin SG, Holmans PA, O’Donovan M, Owen MJ,896
Williams J (2009) Genome-wide association study identifies897
variants at CLU and PICALM associated with Alzheimer’s 898
disease. Nat Genet 41, 1088-1093. 899
[22] Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J- 900
C, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa 901
JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas 902
C, Richards A, Ivanov D, Widdowson C, Chapman J, 903
Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, 904
Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, 905
Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, 906
Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, 907
Love S, Kehoe PG, Hooper NM, Vardy ERLC, Hardy J, 908
Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, 909
Ruther E, Schurmann B, Heun R, Kolsch H, van den Bussche 910
H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich 911
L, Hampel H, Gallacher J, Hull M, Rujescu D, Giegling I, 912
Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, Morris 913
JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De yn 914
PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, 915
McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw 916
CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, 917
Nothen MM, Moebus S, Jockel K-H, Klopp N, Wichmann 918
HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, 919
Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen 920
RC, van Duijn CM, Breteler MMB, Ikram MA, DeSte- 921
fano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri 922
S, Berr C, Campion D, Epelbaum J, Dartigues J-F, Tzou- 923
rio C, Alperovitch A, Lathrop M, Feulner TM, Friedrich P, 924
Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus 925
S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, 926
Snaedal J, Bjornsson S, Jonsson PV, Chouraki V, Genier- 927
Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika 928
D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank- 929
Garcı´a A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco 930
P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, 931
Sorbi S, Bossu P, Piccardi P, Arosio B, Annoni G, Seripa D, 932
Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, 933
Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschnei- 934
der M, Morgan K, Younkin SG, Owen MJ, O’Donovan M, 935
Amouyel P, Williams J (2011) Common variants at ABCA7, 936
MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are asso- 937
ciated with Alzheimer’s disease. Nat Genet 43, 429-435. 938
[23] Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, 939
Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Lar- 940
son EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager 941
PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin- 942
Taner N, Younkin SG, Cruchaga C, Kauwe JSK, Nowotny 943
P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Bar- 944
mada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva 945
E, George-Hyslop PS, Arnold SE, Barber R, Beach T, Bigio 946
EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, 947
Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux 948
J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, 949
Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber 950
KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko 951
DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, 952
Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, 953
Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, 954
Hyman BT, Jicha GA, Jin L-W, Johnson N, Karlawish J, 955
Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah 956
JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Mar- 957
son DC, Martiniuk F, Mash DC, Masliah E, McCormick 958
WC, McCurry SM, McDavid AN, McKee AC, Mesulam 959
M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, 960
Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary 961
RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, 962
Un
co
rre
cte
d A
uth
or
 P
ro
of
S.J. Andrews et al. / Alzheimer’s Disease Genetics and Cognition 23
Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski963
ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA,964
Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM,965
Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA,966
Williamson J, Woltjer RL, Cantwell LB, Dombroski BA,967
Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ,968
Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate969
AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA,970
Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA,971
Farrer LA, Schellenberg GD (2011) Common variants at972
MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are asso-973
ciated with late-onset Alzheimer’s disease. Nat Genet 43,974
436-441.975
[24] Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gud-976
nason V, Boada M, Bis JC, Smith AV, Carassquillo MM,977
Lambert J-C, Harold D, Schrijvers EMC, Ramı´rez-Lorca R,978
Debette S, Longstreth WT, Janssens ACJW, Pankratz VS,979
Dartigues J-F, Hollingworth P, Aspelund T, Herna´ ndez I,980
Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio981
C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko YS,982
Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta983
J, Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA,984
Graff-Radford NR, Campion D, Auerbach S, Rice K, Hof-985
man A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au986
R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz987
A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer988
LJ, Lo´pez OL, van Duijn CM, Breteler MMB, CHARGE989
Consortium, GERAD1 Consortium, EADI1 Consortium990
(2010) Genome-wide analysis of genetic loci associated991
with Alzheimer disease. JAMA 303, 1832-1840.992
[25] Lambert J-C, Heath S, Even G, Campion D, Sleegers K,993
Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tav-994
ernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet995
N, Barberger-Gateau P, Engelborghs S, De yn P, Mateo I,996
Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo997
MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez998
V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Pic-999
cardi P, Annoni G, Seripa D, Galimberti D, Hannequin D,1000
Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues1001
J-F, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A,1002
Lathrop M, Amouyel P (2009) Genome-wide association1003
study identifies variants at CLU and CR1 associated with1004
Alzheimer’s disease. Nat Genet 41, 1094-1099.1005
[26] Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims1006
R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW,1007
Grenier-Boley B, Russo G, Thorton-Wells TA, Jones N,1008
Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D,1009
Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt1010
H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi1011
SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N,1012
Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston1013
JA, Evans D, Lovestone S, Letenneur L, Moron FJ, Rubin-1014
sztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fievet N,1015
Huentelman MW, Gill M, Brown K, Kamboh MI, Keller1016
L, Barberger-Gateau P, McGuiness B, Larson EB, Green R,1017
Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva1018
E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A,1019
Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossu P, Spalletta1020
G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC,1021
Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C,1022
Galimberti D, Mancuso M, Matthews F, Moebus S, Mecocci1023
P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido1024
M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M,1025
Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM,1026
Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O,1027
Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin 1028
C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, 1029
Combarros O, O’Donovan MC, Cantwell LB, Soininen H, 1030
Blacker D, Mead S, Mosley THJ, Bennett DA, Harris TB, 1031
Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine 1032
TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, 1033
Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie 1034
K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider 1035
M, Boada M, Hiltuenen M, Martin ER, Schmidt R, Rujescu 1036
D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman 1037
A, Nothen MM, Graff C, Psaty BM, Jones L, Haines JL, 1038
Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, 1039
Farrer LA, van Duijn CM, Van Broeckhoven C, Moskv- 1040
ina V, Seshadri S, Williams J, Schellenberg GD, Amouyel 1041
P (2013) Meta-analysis of 74,046 individuals identifies 11 1042
new susceptibility loci for Alzheimer’s disease. Nat Genet 1043
45, 1452-1458. 1044
[27] Liu JZ, Erlich Y, Pickrell JK (2017) Case-control association 1045
mapping by proxy using family history of disease.NatGenet 1046
49, 325-331. 1047
[28] Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars 1048
SP, Hill WD, Davies G, Ritchie CW, Gale CR, Starr JM, 1049
Goate AM, Porteous DJ, Yang J, Evans KL, Deary IJ, 1050
Wray NR, Visscher PM (2018) GWAS on family history 1051
of Alzheimer’s disease. Transl Psychiatry 8, 99. 1052
[29] Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, 1053
Steinberg S, Sealock J, Karlsson IK, Hagg S, Athanasiu 1054
L, Voyle N, Proitsi P, Witoelar A, Stringer S, Aarsland D, 1055
Almdahl IS, Andersen F, Bergh S, Bettella F, Bjornsson S, 1056
Brækhus A, Bra˚then G, de Leeuw C, Desikan RS, Djurovic 1057
S, Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kid- 1058
dle SJ, Rongve A, Saltvedt I, Sando SB, Selbæk G, Shoai 1059
M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y, 1060
White LR, Hardy J, Hjerling-Leffler J, Sullivan PF, van der 1061
Flier WM, Dobson R, Davis LK, Stefansson H, Stefans- 1062
son K, Pedersen NL, Ripke S, Andreassen OA, Posthuma D 1063
(2019) Genome-wide meta-analysis identifies new loci and 1064
functional pathways influencing Alzheimer’s disease risk. 1065
Nat Genet 51, 404-413. 1066
[30] Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, 1067
Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie- 1068
Wolf A, Bellenguez C, Frizatti A, Chouraki V, Martin ER, 1069
Sleegers K, Badarinarayan N, Jakobsdottir J, Hamilton- 1070
Nelson KL, Moreno-Grau S, Olaso R, Raybould R, Chen Y, 1071
Kuzma AB, Hiltunen M, Morgan T, Ahmad S, Vardarajan 1072
BN, Epelbaum J, Hoffmann P, Boada M, Beecham GW, Gar- 1073
nier J-G, Harold D, Fitzpatrick AL, Valladares O, Moutet 1074
M-L, Gerrish A, Smith AV, Qu L, Bacq D, Denning N, 1075
Jian X, Zhao Y, del Zompo M, Fox NC, Choi S-H, Mateo 1076
I, Hughes JT, Adams HH, Malamon J, Sanchez Garcia F, 1077
Patel Y, Brody JA, Dombroski BA, Naranjo MCD, Dani- 1078
ilidou M, Eiriksdottir G, Mukherjee S, Wallon D, Uphill J, 1079
Aspelund T, Cantwell LB, Garzia F, Galimberti D, Hofer 1080
E, Butkiewicz M, Fin B, Scarpini E, Sarnowski C, Bush 1081
WS, Meslage S, Kornhuber J, White CC, Song Y, Barber 1082
RC, Engelborghs S, Sordon S, Voijnovic D, Adams PM, 1083
Vandenberghe R, Mayhaus M, Cupples LA, Albert MS, De 1084
Deyn PP, Gu W, Himali JJ, Beekly D, Squassina A, Hart- 1085
mann AM, Orellana A, Blacker D, Rodriguez-Rodriguez 1086
E, Lovestone S, Garcia ME, Doody RS, Munoz-Fernadez 1087
C, Sussams R, Lin H, Fairchild TJ, Benito YA, Holmes C, 1088
Karamujic´- ˇComic´ H, Frosch MP, Thonberg H, Maier W, 1089
Roschupkin G, Ghetti B, Giedraitis V, Kawalia A, Li S, 1090
Huebinger RM, Kilander L, Moebus S, Herna´ ndez I, Kam- 1091
boh MI, Brundin R, Turton J, Yang Q, Katz MJ, Concari 1092
Un
co
rre
cte
d A
uth
or
 P
ro
of
24 S.J. Andrews et al. / Alzheimer’s Disease Genetics and Cognition
L, Lord J, Beiser AS, Keene CD, Helisalmi S, Kloszewska1093
I, Kukull WA, Koivisto AM, Lynch A, Ta´ rraga L, Larson1094
EB, Haapasalo A, Lawlor B, Mosley TH, Lipton RB, Sol-1095
frizzi V, Gill M, Longstreth WT, Montine TJ, Frisardi V,1096
Diez-Fairen M, Rivadeneira F, Petersen RC, Deramecourt1097
V, Alvarez I, Salani F, Ciaramella A, Boerwinkle E, Reiman1098
EM, Fie´vet N, Rotter JI, Reisch JS, Hanon O, Cupidi C,1099
Andre Uitterlinden AG, Royall DR, Dufouil C, Maletta RG,1100
de Rojas I, Sano M, Brice A, Cecchetti R, George-Hyslop1101
PS, Ritchie K, Tsolaki M, Tsuang DW, Dubois B, Craig D,1102
Wu C-K, Soininen H, Avramidou D, Albin RL, Fratiglioni1103
L, Germanou A, Apostolova LG, Keller L, Koutroumani M,1104
Arnold SE, Panza F, Gkatzima O, Asthana S, Hannequin D,1105
Whitehead P, Atwood CS, Caffarra P, Hampel H, Quintela1106
I, Carracedo ´A, Lannfelt L, Rubinsztein DC, Barnes LL,1107
Pasquier F, Frolich L, Barral S, McGuinness B, Beach TG,1108
Johnston JA, Becker JT, Passmore P, Bigio EH, Schott JM,1109
Bird TD, Warren JD, Boeve BF, Lupton MK, Bowen JD,1110
Proitsi P, Boxer A, Powell JF, Burke JR, Kauwe JSK, Burns1111
JM, Mancuso M, Buxbaum JD, Bonuccelli U, Cairns NJ,1112
McQuillin A, Cao C, Livingston G, Carlson CS, Bass NJ,1113
Carlsson CM, Hardy J, Carney RM, Bras J, Carrasquillo1114
MM, Guerreiro R, Allen M, Chui HC, Fisher E, Masullo C,1115
Crocco EA, DeCarli C, Bisceglio G, Dick M, Ma L, Duara1116
R, Graff-Radford NR, Evans DA, Hodges A, Faber KM,1117
Scherer M, Fallon KB, Riemenschneider M, Fardo DW,1118
Heun R, Farlow MR, Kolsch H, Ferris S, Leber M, Foroud1119
TM, Heuser I, Galasko DR, Giegling I, Gearing M, Hull M,1120
Geschwind DH, Gilbert JR, Morris J, Green RC, Mayo K,1121
Growdon JH, Feulner T, Hamilton RL, Harrell LE, Drichel1122
D, Honig LS, Cushion TD, Huentelman MJ, Hollingworth1123
P, Hulette CM, Hyman BT, Marshall R, Jarvik GP, Meggy1124
A, Abner E, Menzies GE, Jin L-W, Leonenko G, Real LM,1125
Jun GR, Baldwin CT, Grozeva D, Karydas A, Russo G,1126
Kaye JA, Kim R, Jessen F, Kowall NW, Vellas B, Kramer1127
JH, Vardy E, LaFerla FM, Jo¨ckel K-H, Lah JJ, Dichgans1128
M, Leverenz JB, Mann D, Levey AI, Pickering-Brown S,1129
Lieberman AP (2019) Genetic meta-analysis of diagnosed1130
Alzheimer’s disease identifies new risk loci and implicates1131
A, tau, immunity and lipid processing. Nat Genet 51,1132
414-430.1133
[31] Sims R, van der Lee SJ, Naj AC, Bellenguez C,1134
Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland1135
A, Raybould R, Bis JC, Martin ER, Grenier-Boley B,1136
Heilmann-Heimbach S, Chouraki V, Kuzma AB, Sleegers1137
K, Vronskaya M, Ruiz A, Graham RR, Olaso R, Hoffmann1138
P, Grove ML, Vardarajan BN, Hiltunen M, Nothen MM,1139
White CC, Hamilton-Nelson KL, Epelbaum J, Maier W,1140
Choi S-H, Beecham GW, Dulary C, Herms S, Smith AV,1141
Funk CC, Derbois C, Forstner AJ, Ahmad S, Li H, Bacq1142
D, Harold D, Satizabal CL, Valladares O, Squassina A,1143
Thomas R, Brody JA, Qu L, Sanchez-Juan P, Morgan T,1144
Wolters FJ, Zhao Y, Garcia FS, Denning N, Fornage M,1145
Malamon J, Naranjo MCD, Majounie E, Mosley TH, Dom-1146
broski B, Wallon D, Lupton MK, Dupuis J, Whitehead P,1147
Fratiglioni L, Medway C, Jian X, Mukherjee S, Keller L,1148
Brown K, Lin H, Cantwell LB, Panza F, McGuinness B,1149
Moreno-Grau S, Burgess JD, Solfrizzi V, Proitsi P, Adams1150
HH, Allen M, Seripa D, Pastor P, Cupples LA, Price ND,1151
Hannequin D, Frank-Garcia A, Levy D, Chakrabarty P, Caf-1152
farra P, Giegling I, Beiser AS, Giedraitis V, Hampel H,1153
Garcia ME, Wang X, Lannfelt L, Mecocci P, Eiriksdottir1154
G, Crane PK, Pasquier F, Boccardi V, Henandez I, Barber1155
RC, Scherer M, Ta´ rraga L, Adams PM, Leber M, Chen Y,1156
Albert MS, Riedel-Heller S, Emilsson V, Beekly D, Braae1157
A, Schmidt R, Blacker D, Masullo C, Schmidt H, Doody RS, 1158
Spalletta G, Longstreth WTJ, Fairchild TJ, Bossu` P, Lo´pez 1159
OL, Frosch MP, Sacchinelli E, Ghetti B, Yang Q, Huebinger 1160
RM, Jessen F, Li S, Kamboh MI, Morris J, Sotolongo-Grau 1161
O, Katz MJ, Corcoran C, Dunstan M, Braddel A, Thomas C, 1162
Meggy A, Marshall R, Gerrish A, Chapman J, Aguilar M, 1163
Taylor S, Hill M, Fairen MD, Hodges A, Vellas B, Soininen 1164
H, Kloszewska I, Daniilidou M, Uphill J, Patel Y, Hughes 1165
JT, Lord J, Turton J, Hartmann AM, Cecchetti R, Fenoglio 1166
C, Serpente M, Arcaro M, Caltagirone C, Orfei MD, Cia- 1167
ramella A, Pichler S, Mayhaus M, Gu W, Lleo A, Fortea J, 1168
Blesa R, Barber IS, Brookes K, Cupidi C, Maletta RG, Car- 1169
rell D, Sorbi S, Moebus S, Urbano M, Pilotto A, Kornhuber 1170
J, Bosco P, Todd S, Craig D, Johnston J, Gill M, Lawlor 1171
B, Lynch A, Fox NC, Hardy J, Albin RL, Apostolova LG, 1172
Arnold SE, Asthana S, Atwood CS, Baldwin CT, Barnes LL, 1173
Barral S, Beach TG, Becker JT, Bigio EH, Bird TD, Boeve 1174
BF, Bowen JD, Boxer A, Burke JR, Burns JM, Buxbaum JD, 1175
Cairns NJ, Cao C, Carlson CS, Carlsson CM, Carney RM, 1176
Carrasquillo MM, Carroll SL, Diaz CC, Chui HC, Clark 1177
DG, Cribbs DH, Crocco EA, DeCarli C, Dick M, Duara R, 1178
Evans DA, Faber KM, Fallon KB, Fardo DW, Farlow MR, 1179
Ferris S, Foroud TM, Galasko DR, Gearing M, Geschwind 1180
DH, Gilbert JR, Graff-Radford NR, Green RC, Growdon 1181
JH, Hamilton RL, Harrell LE, Honig LS, Huentelman MJ, 1182
Hulette CM, Hyman BT, Jarvik GP, Abner E, Jin L-W, Jun 1183
G, Karydas A, Kaye JA, Kim R, Kowall NW, Kramer JH, 1184
LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieber- 1185
man AP, Lunetta KL, Lyketsos CG, Marson DC, Martiniuk 1186
F, Mash DC, Masliah E, McCormick WC, McCurry SM, 1187
McDavid AN, McKee AC, Mesulam M, Miller BL, Miller 1188
CA, Miller JW, Morris JC, Murrell JR, Myers AJ, O’Bryant 1189
S, Olichney JM, Pankratz VS, Parisi JE, Paulson HL, Perry 1190
W, Peskind E, Pierce A, Poon WW, Potter H, Quinn JF, Raj 1191
A, Raskind M, Reisberg B, Reitz C, Ringman JM, Rober- 1192
son ED, Rogaeva E, Rosen HJ, Rosenberg RN, Sager MA, 1193
Saykin AJ, Schneider JA, Schneider LS, Seeley WW, Smith 1194
AG, Sonnen JA, Spina S, Stern RA, Swerdlow RH, Tanzi 1195
RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Van 1196
Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP, Wein- 1197
traub S, Welsh-Bohmer KA, Wilhelmsen KC, Williamson J, 1198
Wingo TS, Woltjer RL, Wright CB, Yu C-E, Yu L, Garzia F, 1199
Golamaully F, Septier G, Engelborghs S, Vandenberghe R, 1200
De Deyn PP, Fernadez CM, Benito YA, Thonberg H, Forsell 1201
C, Lilius L, Kinhult-Stahlbom A, Kilander L, Brundin R, 1202
Concari L, Helisalmi S, Koivisto AM, Haapasalo A, Derme- 1203
court V, Fie´vet N, Hanon O, Dufouil C, Brice A, Ritchie K, 1204
Dubois B, Himali JJ, Keene CD, Tschanz J, Fitzpatrick AL, 1205
Kukull WA, Norton M, Aspelund T, Larson EB, Munger 1206
R, Rotter JI, LIPTON RB, Bullido MJ, Hofman A, Mon- 1207
tine TJ, Coto E, Boerwinkle E, Petersen RC, Alvarez V, 1208
Rivadeneira F, Reiman EM, Gallo M, O’Donnell CJ, Reisch 1209
JS, Bruni AC, Royall DR, Dichgans M, Sano M, Galimberti 1210
D, St George-Hyslop P, Scarpini E, Tsuang DW, Mancuso 1211
M, Bonuccelli U, Winslow AR, Daniele A, Wu C-K, Peters 1212
O, Nacmias B, Riemenschneider M, Heun R, Brayne C, 1213
Rubinsztein DC, Bras J, Guerreiro R, Al-Chalabi A, Shaw 1214
CE, Collinge J, Mann D, Tsolaki M, Clarimon J, Sussams 1215
R, Lovestone S, O’Donovan MC, Owen MJ, Behrens TW, 1216
Mead S, Goate AM, Uitterlinden AG, Holmes C, Cruchaga 1217
C, Ingelsson M, Bennett DA, Powell J, Golde TE, Graff 1218
C, De Jager PL, Morgan K, Ertekin-Taner N, Combarros 1219
O, Psaty BM, Passmore P, Younkin SG, Berr C, Gudna- 1220
son V, Rujescu D, Dickson DW, Dartigues J-F, DeStefano 1221
AL, Ortega-Cubero S, Hakonarson H, Campion D, Boada 1222
Un
co
rre
cte
d A
uth
or
 P
ro
of
S.J. Andrews et al. / Alzheimer’s Disease Genetics and Cognition 25
M, Kauwe JK, Farrer LA, Van Broeckhoven C, Ikram MA,1223
Jones L, Haines JL, Tzourio C, Launer LJ, Escott-Price V,1224
Mayeux R, Deleuze J-F, Amin N, Holmans PA, Pericak-1225
Vance MA, Amouyel P, van Duijn CM, Ramirez A, Wang1226
L-S, Lambert J-C, Seshadri S, Williams J, Schellenberg1227
GD (2017) Rare coding variants in PLCG2, ABI3, and1228
TREM2 implicate microglial-mediated innate immunity in1229
Alzheimer’s disease. Nat Genet 49, 1373-1384.1230
[32] Small BJ, Rosnick CB, Fratiglioni L, Ba¨ckman L (2004)1231
Apolipoprotein E and cognitive performance: A meta-1232
analysis. Psychol Aging 19, 592-600.1233
[33] Wisdom NM, Callahan JL, Hawkins KA (2011) The effects1234
of apolipoprotein E on non-impaired cognitive functioning:1235
A meta-analysis. Neurobiol Aging 32, 63-74.1236
[34] Andrews S, McFall GP (2017) Association of non-APOE1237
Alzheimer’s genetic risk loci with cognitive aging: A sys-1238
tematic review. PROSPERO, CRD42017075685.1239
[35] Cochrane (2016) Covidence.1240
[36] Lezak MD, Howieson DB, Loring DW, Fischer JS (2004)1241
Neuropsychological assessment (4th ed). Oxford University1242
Press, New York.1243
[37] Sohani ZN, Meyre D, de Souza RJ, Joseph PG, Gandhi M,1244
Dennis BB, Norman G, Anand SS (2015) Assessing the1245
quality of published genetic association studies in meta-1246
analyses: The quality of genetic studies (Q-Genie) tool.1247
BMC Genet 16, 50.1248
[38] Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J,1249
de Leeuw CA, Nagel M, Awasthi S, Barr PB, Coleman JRI,1250
Grasby KL, Hammerschlag AR, Kaminski JA, Karlsson R,1251
Krapohl E, Lam M, Nygaard M, Reynolds CA, Trampush1252
JW, Young H, Zabaneh D, Hagg S, Hansell NK, Karlsson1253
IK, Linnarsson S, Montgomery GW, Munoz-Manchado AB,1254
Quinlan EB, Schumann G, Skene NG, Webb BT, White T,1255
Arking DE, Avramopoulos D, Bilder RM, Bitsios P, Burdick1256
KE, Cannon TD, Chiba-Falek O, Christoforou A, Cirulli ET,1257
Congdon E, Corvin A, Davies G, Deary IJ, DeRosse P, Dick-1258
inson D, Djurovic S, Donohoe G, Conley ED, Eriksson JG,1259
Espeseth T, Freimer NA, Giakoumaki S, Giegling I, Gill M,1260
Glahn DC, Hariri AR, Hatzimanolis A, Keller MC, Knowles1261
E, Koltai D, Konte B, Lahti J, Le Hellard S, Lencz T, Liewald1262
DC, London E, Lundervold AJ, Malhotra AK, Melle I, Mor-1263
ris D, Need AC, Ollier W, Palotie A, Payton A, Pendleton N,1264
Poldrack RA, Raikkonen K, Reinvang I, Roussos P, Rujescu1265
D, Sabb FW, Scult MA, Smeland OB, Smyrnis N, Starr JM,1266
Steen VM, Stefanis NC, Straub RE, Sundet K, Tiemeier H,1267
Voineskos AN, Weinberger DR, Widen E, Yu J, Abecasis1268
G, Andreassen OA, Breen G, Christiansen L, Debrabant B,1269
Dick DM, Heinz A, Hjerling-Leffler J, Ikram MA, Kendler1270
KS, Martin NG, Medland SE, Pedersen NL, Plomin R, Pold-1271
erman TJC, Ripke S, van der Sluis S, Sullivan PF, Vrieze SI,1272
Wright MJ, Posthuma D (2018) Genome-wide association1273
meta-analysis in 269,867 individuals identifies new genetic1274
and functional links to intelligence. Nat Genet 50, 912-919.1275
[39] Davies G, Lam M, Harris SE, Trampush JW, Luciano M,1276
Hill WD, Hagenaars SP, Ritchie SJ, Marioni RE, Fawns-1277
Ritchie C, Liewald DCM, Okely JA, Ahola-Olli AV, Barnes1278
CLK, Bertram L, Bis JC, Burdick KE, Christoforou A,1279
DeRosse P, Djurovic S, Espeseth T, Giakoumaki S, Gid-1280
daluru S, Gustavson DE, Hayward C, Hofer E, Ikram MA,1281
Karlsson R, Knowles E, Lahti J, Leber M, Li S, Mather1282
KA, Melle I, Morris D, Oldmeadow C, Palviainen T, Pay-1283
ton A, Pazoki R, Petrovic K, Reynolds CA, Sargurupremraj1284
M, Scholz M, Smith JA, Smith AV, Terzikhan N, Thala-1285
muthu A, Trompet S, van der Lee SJ, Ware EB, Windham1286
BG, Wright MJ, Yang J, Yu J, Ames D, Amin N, Amouyel1287
P, Andreassen OA, Armstrong NJ, Assareh AA, Attia JR, 1288
Attix D, Avramopoulos D, Bennett DA, Bohmer AC, Boyle 1289
PA, Brodaty H, Campbell H, Cannon TD, Cirulli ET, Con- 1290
gdon E, Conley ED, Corley J, Cox SR, Dale AM, Dehghan 1291
A, Dick D, Dickinson D, Eriksson JG, Evangelou E, Faul 1292
JD, Ford I, Freimer NA, Gao H, Giegling I, Gillespie NA, 1293
Gordon SD, Gottesman RF, Griswold ME, Gudnason V, 1294
Harris TB, Hartmann AM, Hatzimanolis A, Heiss G, Hol- 1295
liday EG, Joshi PK, Kahonen M, Kardia SLR, Karlsson I, 1296
Kleineidam L, Knopman DS, Kochan NA, Konte B, Kwok 1297
JB, Le Hellard S, Lee T, Lehtimaki T, Li S-C, Liu T, Koini M, 1298
London E, Longstreth WTJ, Lo´pez OL, Loukola A, Luck 1299
T, Lundervold AJ, Lundquist A, Lyytikainen L-P, Martin 1300
NG, Montgomery GW, Murray AD, Need AC, Noordam 1301
R, Nyberg L, Ollier W, Papenberg G, Pattie A, Polasek O, 1302
Poldrack RA, Psaty BM, Reppermund S, Riedel-Heller SG, 1303
Rose RJ, Rotter JI, Roussos P, Rovio SP, Saba Y, Sabb FW, 1304
Sachdev PS, Satizabal CL, Schmid M, Scott RJ, Scult MA, 1305
Simino J, Slagboom PE, Smyrnis N, Soumare A, Stefanis 1306
NC, Stott DJ, Straub RE, Sundet K, Taylor AM, Taylor KD, 1307
Tzoulaki I, Tzourio C, Uitterlinden A, Vitart V, Voineskos 1308
AN, Kaprio J, Wagner M, Wagner H, Weinhold L, Wen KH, 1309
Widen E, Yang Q, Zhao W, Adams HHH, Arking DE, Bilder 1310
RM, Bitsios P, Boerwinkle E, Chiba-Falek O, Corvin A, De 1311
Jager PL, Debette S, Donohoe G, Elliott P, Fitzpatrick AL, 1312
Gill M, Glahn DC, Hagg S, Hansell NK, Hariri AR, Ikram 1313
MK, Jukema JW, Vuoksimaa E, Keller MC, Kremen WS, 1314
Launer L, Lindenberger U, Palotie A, Pedersen NL, Pendle- 1315
ton N, Porteous DJ, Raikkonen K, Raitakari OT, Ramirez 1316
A, Reinvang I, Rudan I, Rujescu D, Schmidt R, Schmidt 1317
H, Schofield PW, Schofield PR, Starr JM, Steen VM, Trol- 1318
lor JN, Turner ST, van Duijn CM, Villringer A, Weinberger 1319
DR, Weir DR, Wilson JF, Malhotra A, McIntosh AM, Gale 1320
CR, Seshadri S, Mosley THJ, Bressler J, Lencz T, Deary 1321
IJ (2018) Study of 300,486 individuals identifies 148 inde- 1322
pendent genetic loci influencing general cognitive function. 1323
Nat Commun 9, 2098. 1324
[40] Hill WD, Marioni RE, Maghzian O, Ritchie SJ, Hagenaars 1325
SP, McIntosh AM, Gale CR, Davies G, Deary IJ (2018) A 1326
combined analysis of genetically correlated traits identifies 1327
187 loci and a role for neurogenesis and myelination in 1328
intelligence. Mol Psychiatry 15, 201. 1329
[41] Andrews SJ, Das D, Anstey KJ, Easteal S (2017) Late 1330
onset Alzheimer’s disease risk variants in cognitive decline: 1331
The PATH Through Life Study. J Alzheimers Dis 57, 1332
423-436. 1333
[42] Carrasquillo MM, Crook JE, Pedraza O, Thomas CS, 1334
Pankratz VS, Allen M, Nguyen T, Malphrus KG, Ma L, 1335
Bisceglio GD, Roberts RO, Lucas JA, Smith GE, Ivnik RJ, 1336
Machulda MM, Graff-Radford NR, Petersen RC, Younkin 1337
SG, Ertekin-Taner N (2015) Late-onset Alzheimer’s risk 1338
variants in memory decline, incident mild cognitive impair- 1339
ment, and Alzheimer’s disease. Neurobiol Aging 36, 1340
60-67. 1341
[43] Engelman CD, Koscik RL, Jonaitis EM, Okonkwo OC, 1342
Hermann BP, La Rue A, Sager MA (2013) Interaction 1343
between two cholesterol metabolism genes influences mem- 1344
ory: Findings from the Wisconsin Registry for Alzheimer’s 1345
Prevention. J Alzheimers Dis 36, 749-757. 1346
[44] Bressler J, Mosley TH, Penman A, Gottesman RF, Wind- 1347
ham BG, Knopman DS, Wruck LM, Boerwinkle E (2017) 1348
Genetic variants associated with risk of Alzheimer’s disease 1349
contribute to cognitive change in midlife: The Atheroscle- 1350
rosis Risk in Communities Study. Am J Med Genet B 1351
Neuropsychiatr Genet 174, 269-282 1352
Un
co
rre
cte
d A
uth
or
 P
ro
of
26 S.J. Andrews et al. / Alzheimer’s Disease Genetics and Cognition
[45] Nettiksimmons J, Tranah G, Evans DS, Yokoyama JS, Yaffe1353
K (2016) Gene-based aggregate SNP associations between1354
candidate AD genes and cognitive decline. AGE 38, 41.1355
[46] Vivot A, Glymour MM, Tzourio C, Amouyel P, Chene G,1356
Dufouil C (2015) Association of Alzheimer’s related geno-1357
types with cognitive decline in multiple domains: Results1358
from the Three-City Dijon study. Mol Psychiatry 20, 1173-1359
1178.1360
[47] Hamilton G, Harris SE, Davies G, Liewald DC, Tenesa A,1361
Starr JM, Porteous D, Deary IJ (2011) Alzheimer’s disease1362
genes are associated with measures of cognitive ageing in1363
the lothian birth cohorts of 1921 and 1936. Int J Alzheimers1364
Dis 2011, 505984.1365
[48] Verhaaren BFJ, Vernooij MW, Koudstaal PJ, Uitterlinden1366
AG, van Duijn CM, Hofman A, Breteler MMB, Ikram MA1367
(2013) Alzheimer’s disease genes and cognition in the non-1368
demented general population. Biol Psychiatry 73, 429-434.1369
[49] Zhang C, Pierce BL (2014) Genetic susceptibility to accel-1370
erated cognitive decline in the US Health and Retirement1371
Study. Neurobiol Aging 35, 1512.e11-8.1372
[50] Hagenaars SP, Cox SR, Hill WD, Davies G, Liewald DCM,1373
CHARGE consortium Cognitive Working Group, Harris1374
SE, McIntosh AM, Gale CR, Deary IJ (2017) Genetic con-1375
tributions to Trail Making Test performance in UK Biobank.1376
Mol Psychiatry 23, 1575-1583.1377
[51] Thambisetty M, Beason-Held LL, An Y, Kraut M, Nalls M,1378
Hernandez DG, Singleton AB, Zonderman AB, Ferrucci L,1379
Lovestone S, Resnick SM (2013) Alzheimer risk variant1380
CLU and brain function during aging. Biol Psychiatry 73,1381
399-405.1382
[52] Pedraza O, Allen M, Jennette K, Carrasquillo M, Crook J,1383
Serie D, Pankratz VS, Palusak R, Nguyen T, Malphrus K,1384
Ma L, Bisceglio G, Roberts RO, Lucas JA, Ivnik RJ, Smith1385
GE, Graff-Radford NR, Petersen RC, Younkin SG, Ertekin-1386
Taner N (2014) Evaluation of memory endophenotypes for1387
association with CLU, CR1, and PICALM variants in black1388
and white subjects. Alzheimers Dement 10, 205-213.1389
[53] Sweet RA, Seltman H, Emanuel JE, Lo´pez OL, Becker JT,1390
Bis JC, Weamer EA, DeMichele-Sweet MAA, Kuller LH1391
(2012) Effect of Alzheimer’s disease risk genes on trajec-1392
tories of cognitive function in the Cardiovascular Health1393
Study. Am J Psychiatry 169, 954-962.1394
[54] Mengel-From J, Christensen K, McGue M, Christiansen L1395
(2011) Genetic variations in the CLU and PICALM genes1396
are associated with cognitive function in the oldest old.1397
Neurobiol Aging 32, 554.e7-11.1398
[55] Mengel-From J, Thinggaard M, Lindahl-Jacobsen R,1399
McGue M, Christensen K, Christiansen L (2013) CLU1400
genetic variants and cognitive decline among elderly and1401
oldest old. PLoS One 8, e79105.1402
[56] Debette S, Ibrahim-Verbaas CA, Bressler J, Schuur M,1403
Smith A, Bis JC, Davies G, Wolf C, Gudnason V, Chib-1404
nik LB, Yang Q, DeStefano AL, de Quervain DJF, Srikanth1405
V, Lahti J, Grabe HJ, Smith JA, Priebe L, Yu L, Karbalai1406
N, Hayward C, Wilson JF, Campbell H, Petrovic K, For-1407
nage M, Chauhan G, Yeo R, Boxall R, Becker J, Stegle1408
O, Mather KA, Chouraki V, Sun Q, Rose LM, Resnick S,1409
Oldmeadow C, Kirin M, Wright AF, Jonsdottir MK, Au R,1410
Becker A, Amin N, Nalls MA, Turner ST, Kardia SLR, Oos-1411
tra B, Windham G, Coker LH, Zhao W, Knopman DS, Heiss1412
G, Griswold ME, Gottesman RF, Vitart V, Hastie ND, Zgaga1413
L, Rudan I, Polasek O, Holliday EG, Schofield P, Choi S-H,1414
Tanaka T, An Y, Perry RT, Kennedy RE, Sale MM, Wang1415
J, Wadley VG, Liewald DC, Ridker PM, Gow AJ, Pattie A,1416
Starr JM, Porteous D, Liu X, Thomson R, Armstrong NJ,1417
Eiriksdottir G, Assareh AA, Kochan NA, Widen E, Palotie 1418
A, Hsieh Y-C, Eriksson JG, Vogler C, van Swieten JC, Shul- 1419
man JM, Beiser A, Rotter J, Schmidt CO, Hoffmann W, 1420
Nothen MM, Ferrucci L, Attia J, Uitterlinden AG, Amouyel 1421
P, Dartigues J-F, Amieva H, Raikkonen K, Garcia M, Wolf 1422
PA, Hofman A, Longstreth WTJ, Psaty BM, Boerwinkle 1423
E, DeJager PL, Sachdev PS, Schmidt R, Breteler MMB, 1424
Teumer A, Lo´pez OL, Cichon S, Chasman DI, Grodstein F, 1425
Muller-Myhsok B, Tzourio C, Papassotiropoulos A, Ben- 1426
nett DA, Ikram MA, Deary IJ, van Duijn CM, Launer L, 1427
Fitzpatrick AL, Seshadri S, Mosley THJ (2015) Genome- 1428
wide studies of verbal declarative memory in nondemented 1429
older people: The Cohorts for Heart and Aging Research 1430
in Genomic Epidemiology consortium. Biol Psychiatry 77, 1431
749-763. 1432
[57] Chibnik LB, Shulman JM, Leurgans SE, Schneider JA, Wil- 1433
son RS, Tran D, Aubin C, Buchman AS, Heward CB, Myers 1434
AJ, Hardy JA, Huentelman MJ, Corneveaux JJ, Reiman EM, 1435
Evans DA, Bennett DA, De Jager PL (2011) CR1 is associ- 1436
ated with amyloid plaque burden and age-related cognitive 1437
decline. Ann Neurol 69, 560-569. 1438
[58] Davies G, Marioni RE, Liewald DC, Hill WD, Hagenaars 1439
SP, Harris SE, Ritchie SJ, Luciano M, Fawns-Ritchie C, 1440
Lyall D, Cullen B, Cox SR, Hayward C, Porteous DJ, Evans 1441
J, McIntosh AM, Gallacher J, Craddock N, Pell JP, Smith 1442
DJ, Gale CR, Deary IJ (2016) Genome-wide association 1443
study of cognitive functions and educational attainment in 1444
UK Biobank (N=112 151). Mol Psychiatry 21, 758-767. 1445
[59] Raj T, Chibnik LB, McCabe C, Wong A, Replogle JM, Yu 1446
L, Gao S, Unverzagt FW, Stranger B, Murrell J, Barnes L, 1447
Hendrie HC, Foroud T, Krichevsky A, Bennett DA, Hall 1448
KS, Evans DA, De Jager PL (2016) Genetic architecture of 1449
age-related cognitive decline in African Americans. Neurol 1450
Genet 3, e125. 1451
[60] Sniekers S, Stringer S, Watanabe K, Jansen PR, Coleman 1452
JRI, Krapohl E, Taskesen E, Hammerschlag AR, Okbay A, 1453
Zabaneh D, Amin N, Breen G, Cesarini D, Chabris CF, 1454
Iacono WG, Ikram MA, Johannesson M, Koellinger P, Lee 1455
JJ, Magnusson PKE, McGue M, Miller MB, Ollier WER, 1456
Payton A, Pendleton N, Plomin R, Rietveld CA, Tiemeier 1457
H, van Duijn CM, Posthuma D (2017) Genome-wide asso- 1458
ciation meta-analysis of 78,308 individuals identifies new 1459
loci and genes influencing human intelligence. Nat Genet 1460
49, 1107-1112. 1461
[61] Davies G, Armstrong N, Bis JC, Bressler J, Chouraki V, 1462
Giddaluru S, Hofer E, Ibrahim-Verbaas CA, Kirin M, Lahti 1463
J, van der Lee SJ, Le Hellard S, Liu T, Marioni RE, Old- 1464
meadow C, Postmus I, Smith AV, Smith JA, Thalamuthu 1465
A, Thomson R, Vitart V, Wang J, Yu L, Zgaga L, Zhao 1466
W, Boxall R, Harris SE, Hill WD, Liewald DC, Luciano 1467
M, Adams H, Ames D, Amin N, Amouyel P, Assareh AA, 1468
Au R, Becker JT, Beiser A, Berr C, Bertram L, Boerwin- 1469
kle E, Buckley BM, Campbell H, Corley J, De Jager PL, 1470
Dufouil C, Eriksson JG, Espeseth T, Faul JD, Ford I, Scot- 1471
land G, Gottesman RF, Griswold ME, Gudnason V, Harris 1472
TB, Heiss G, Hofman A, Holliday EG, Huffman J, Kardia 1473
SLR, Kochan N, Knopman DS, Kwok JB, Lambert JC, Lee 1474
T, Li G, Li S-C, Loitfelder M, Lopez OL, Lundervold AJ, 1475
Lundqvist A, Mather KA, Mirza SS, Nyberg L, Oostra BA, 1476
Palotie A, Papenberg G, Pattie A, Petrovic K, Polasek O, 1477
Psaty BM, Redmond P, Reppermund S, Rotter JI, Schmidt 1478
H, Schuur M, Schofield PW, Scott RJ, Steen VM, Stott DJ, 1479
van Swieten JC, Taylor KD, Trollor J, Trompet S, Uitter- 1480
linden AG, Weinstein G, Widen E, Windham BG, Jukema 1481
JW, Wright AF, Wright MJ, Yang Q, Amieva H, Attia JR, 1482
Un
co
rre
cte
d A
uth
or
 P
ro
of
S.J. Andrews et al. / Alzheimer’s Disease Genetics and Cognition 27
Bennett DA, Brodaty H, de Craen AJM, Hayward C, Ikram1483
MA, Lindenberger U, Nilsson L-G, Porteous DJ, Raikkonen1484
K, Reinvang I, Rudan I, Sachdev PS, Schmidt R, Schofield1485
PR, Srikanth V, Starr JM, Turner ST, Weir DR, Wilson JF,1486
van Duijn C, Launer L, Fitzpatrick AL, Seshadri S, Mosley1487
THJ, Deary IJ (2015) Genetic contributions to variation1488
in general cognitive function: A meta-analysis of genome-1489
wide association studies in the CHARGE consortium (N=531490
949). Mol Psychiatry 20, 183-192.1491
[62] Houlihan LM, Harris SE, Luciano M, Gow AJ, Starr JM,1492
Visscher PM, Deary IJ (2009) Replication study of candi-1493
date genes for cognitive abilities: The Lothian Birth Cohort1494
1936. Genes Brain Behav 8, 238-247.1495
[63] Liang Y, Li H, Lv C, Shu N, Chen K, Li X, Zhang J,1496
Hu L, Zhang Z (2015) Sex moderates the effects of the1497
Sorl1 gene rs2070045 polymorphism on cognitive impair-1498
ment and disruption of the cingulum integrity in healthy1499
elderly. Neuropsychopharmacology 40, 2487-2487.1500
[64] Li H, Lv CL, Yang CS, Wei DF, Chen KW, Li SW, Zhang1501
ZJ (2017) SORL1 rs1699102 polymorphism modulates age-1502
related cognitive decline and gray matter volume reduction1503
in non-demented individuals. Eur J Neurol 24, 187-194.1504
[65] Liu F, Ikram MA, Janssens ACJW, Schuur M, de Koning I,1505
Isaacs A, Struchalin M, Uitterlinden AG, Dunnen den JT,1506
Sleegers K, Bettens K, Van Broeckhoven C, van Swieten J,1507
Hofman A, Oostra BA, Aulchenko YS, Breteler MMB, van1508
Duijn CM (2009) A study of the SORL1 gene in Alzheimer’s1509
disease and cognitive function. J Alzheimers Dis 18, 51-64.1510
[66] Reynolds CA, Zavala C, Gatz M, Vie L, Johansson B, Malm-1511
berg B, Ingelsson E, Prince JA, Pedersen NL (2013) Sortilin1512
receptor 1 predicts longitudinal cognitive change.Neurobiol1513
Aging 34, 1710.e11-1710.e18.1514
[67] Liu Y, Yu J-T, Wang H-F, Hao X-K, Yang Y-F, Jiang1515
T, Zhu X-C, Cao L, Zhang D-Q, Tan L (2014) Associ-1516
ation between NME8 locus polymorphism and cognitive1517
decline, cerebrospinal fluid and neuroimaging biomarkers1518
in Alzheimer’s disease. PLoS One 9, e114777.1519
[68] Darst BF, Koscik RL, Racine AM, Oh JM, Krause RA,1520
Carlsson CM, Zetterberg H, Blennow K, Christian BT,1521
Bendlin BB, Okonkwo OC, Hogan KJ, Hermann BP,1522
Sager MA, Asthana S, Johnson SC, Engelman CD (2017)1523
Pathway-specific polygenic risk scores as predictors of1524
amyloid- deposition and cognitive function in a sample1525
at increased risk for Alzheimer’s disease. J Alzheimers Dis1526
55, 473-484.1527
[69] Christoforou A, Espeseth T, Davies G, Fernandes CPD,1528
Giddaluru S, Mattheisen M, Tenesa A, Harris SE, Liewald1529
DC, Payton A, Ollier W, Horan M, Pendleton N, Haggarty1530
P, Djurovic S, Herms S, Hoffman P, Cichon S, Starr JM,1531
Lundervold A, Reinvang I, Steen VM, Deary IJ, Le Hel-1532
lard S (2014) GWAS-based pathway analysis differentiates1533
between fluid and crystallized intelligence. Genes Brain1534
Behav 13, 663-674.1535
[70] Ferencz B, Jonsson Laukka E, Welmer A-K, Kalpouzos1536
G, Angleman S, Keller L, Graff C, Lovden M, Backman1537
L (2014) The benefits of staying active in old age: Physi-1538
cal activity counteracts the negative influence of PICALM,1539
BIN1, and CLU risk alleles on episodic memory function-1540
ing. Psychol Aging 29, 440-449.1541
[71] Marden JR, Mayeda ER, Walter S, Vivot A, Tchetgen1542
Tchetgen EJ, Kawachi I, Glymour MM (2016) Using an1543
Alzheimer disease polygenic risk score to predict mem-1544
ory decline in black and white americans over 14 years of1545
follow-up. Alzheimer Dis Assoc Disord 30, 195-202.1546
[72] Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De 1547
Jager PL, Smoller JW, Sabuncu MR, Alzheimer’s Disease 1548
Neuroimaging Initiative (2016) Polygenic risk of Alzheimer 1549
disease is associated with early- and late-life processes. 1550
Neurology 87, 481-488. 1551
[73] Liebers DT, Pirooznia M, Seiffudin F, Musliner KL, Zandi 1552
PP, Goes FS (2016) Polygenic risk of schizophrenia and 1553
cognition in a population-based survey of older adults. 1554
Schizophr Bull 42, 984-991. 1555
[74] Marioni RE, Campbell A, Hagenaars SP, Nagy R, Amador 1556
C, Hayward C, Porteous DJ, Visscher PM, Deary IJ (2017) 1557
Genetic stratification to identify risk groups for Alzheimer’s 1558
disease. J Alzheimers Dis 57, 275-283. 1559
[75] Ge T, Sabuncu MR, Smoller JW, Sperling RA, Mormino 1560
EC, for the Alzheimer’s Disease Neuroimaging Initiative 1561
(2018) Dissociable influences of APOE4 and polygenic 1562
risk of AD dementia on amyloid and cognition. Neurology 1563
90, e1605-e1612. 1564
[76] Dudbridge F (2013) Power and predictive accuracy of poly- 1565
genic risk scores. PLoS Genet 9, e1003348. 1566
[77] Payton A (2009) The impact of genetic research on our 1567
understanding of normal cognitive ageing: 1995 to 2009. 1568
Neuropsychol Rev 19, 451-477. 1569
[78] De Jager PL, Shulman JM, Chibnik LB, Keenan BT, Raj T, 1570
Wilson RS, Yu L, Leurgans SE, Tran D, Aubin C, Anderson 1571
CD, Biffi A, Corneveaux JJ, Huentelman MJ, Rosand J, 1572
Daly MJ, Myers AJ, Reiman EM, Bennett DA, Evans DA 1573
(2012) A genome-wide scan for common variants affecting 1574
the rate of age-related cognitive decline. Neurobiol Aging 1575
33, 1017.e1-1017.e15. 1576
[79] Lyall DM, Cullen B, Allerhand M, Smith DJ, Mackay 1577
D, Evans J, Anderson J, Fawns-Ritchie C, McIntosh AM, 1578
Deary IJ, Pell JP (2016) Cognitive test scores in UK 1579
Biobank: Data reduction in 480,416 participants and lon- 1580
gitudinal stability in 20,346 participants. PLoS One 11, 1581
e0154222. 1582
[80] Deary IJ, Penke L, Johnson W (2010) The neuroscience 1583
of human intelligence differences. Nat Rev Neurosci 11, 1584
201-211. 1585
[81] Tombaugh TN, McIntyre NJ (1992) The mini-mental state 1586
examination: A comprehensive review. J Am Geriatr Soc 1587
40, 922-935. 1588
[82] Hofer SM, Christensen H, Mackinnon AJ, Korten AE, Jorm 1589
AF, Henderson AS, Easteal S (2002) Change in cognitive 1590
functioning associated with apoE genotype in a community 1591
sample of older adults. Psychol Aging 17, 194-208. 1592
[83] Gross AL, Power MC, Albert MS, Deal JA, Gottesman RF, 1593
Griswold M, Wruck LM, Mosley TH, Coresh J, Sharrett 1594
AR, Bandeen-Roche K (2015) Application of latent variable 1595
methods to the study of cognitive decline when tests change 1596
over time. Epidemiology 26, 878-887. 1597
[84] McCoach DB, Black AC, O’Connell AA (2007) Errors of 1598
inference in structural equation modeling. Psychol Sch 44, 1599
461-470. 1600
[85] Knight RG, Tsui HSL, Abraham WC, Skeaff CM, McMa- 1601
hon JA, Cutfield NJ (2014) Lack of effect of the 1602
apolipoprotein E epsilon4 genotype on cognition during 1603
healthy aging. J Clin Exp Neuropsychol 36, 742-750. 1604
[86] Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Porter 1605
T, Ames D, Fowler C, Rainey-Smith S, Snyder PJ, Martins 1606
RN, Salvado O, Bourgeat P, Rowe CC, Masters CL, Maruff 1607
P (2016) A-related memory decline in APOE 4 noncar- 1608
riers: Implications for Alzheimer disease. Neurology 86, 1609
1635-1642. 1610
Un
co
rre
cte
d A
uth
or
 P
ro
of
28 S.J. Andrews et al. / Alzheimer’s Disease Genetics and Cognition
[87] Liao Y-C, Lee W-J, Hwang J-P, Wang Y-F, Tsai C-F, Wang1611
P-N, Wang S-J, Fuh J-L (2014) ABCA7 gene and the risk of1612
Alzheimer’s disease in Han Chinese in Taiwan. Neurobiol1613
Aging 35, 2423.e7-2423.e13.1614
[88] Gui H, Jiang CQ, Cherny SS, Sham PC, Xu L, Liu B, Jin1615
YL, Zhu T, Zhang WS, Thomas GN, Cheng KK, Lam TH1616
(2014) Influence of Alzheimer’s disease genes on cognitive1617
decline: The Guangzhou Biobank Cohort Study. Neurobiol1618
Aging 35, 2422.e3-8.1619
[89] Davies G, Harris SE, Reynolds CA, Payton A, Knight HM,1620
Liewald DC, Lopez LM, Luciano M, Gow AJ, Corley J,1621
Henderson R, Murray C, Pattie A, Fox HC, Redmond P,1622
Lutz MW, Chiba-Falek O, Linnertz C, Saith S, Haggarty P,1623
McNeill G, Ke X, Ollier W, Horan M, Roses AD, Ponting1624
CP, Porteous DJ, Tenesa A, Pickles A, Starr JM, Whalley LJ,1625
Pedersen NL, Pendleton N, Visscher PM, Deary IJ (2014) A1626
genome-wide association study implicates the APOE locus1627
in nonpathological cognitive ageing. Mol Psychiatry 19,1628
76-87.1629
[90] Barral S, Bird T, Goate A, Farlow MR, Diaz-Arrastia R,1630
Bennett DA, Graff-Radford N, Boeve BF, Sweet RA, Stern1631
Y, Wilson RS, Foroud T, Ott J, Mayeux R (2012) Geno-1632
type patterns at PICALM, CR1, BIN1, CLU, and APOE1633
genes are associated with episodic memory. Neurology 78,1634
1464-1471.1635
[91] Shulman JM, Chibnik LB, Aubin C, Schneider JA, Bennett1636
DA, De Jager PL (2010) Intermediate phenotypes identify1637
divergent pathways to Alzheimer’s disease. PLoS One 5,1638
e11244.1639
[92] McFall GP, Sapkota S, McDermott KL, Dixon RA (2016)1640
Risk-reducing Apolipoprotein E and Clusterin genotypes1641
protect against the consequences of poor vascular health on1642
executive function performance and change in nondemented1643
older adults. Neurobiol Aging 42, 91-100.1644
[93] Qiu L, He Y, Tang H, Zhou Y, Wang J, Zhang W, Chen G, 1645
Zhao F, Ouyang T, Ju B, Li Z, Wang L, Zou L, Gong Q (2016) 1646
Genetically-mediated grey and white matter alteration in 1647
normal elderly individuals with the CLU-C allele gene.Curr 1648
Alzheimer Res 13, 1302-1310. 1649
[94] Keenan BT, Shulman JM, Chibnik LB, Raj T, Tran D, 1650
Sabuncu MR, Alzheimer’s Disease Neuroimaging Initia- 1651
tive, Allen AN, Corneveaux JJ, Hardy JA, Huentelman MJ, 1652
Lemere CA, Myers AJ, Nicholson-Weller A, Reiman EM, 1653
Evans DA, Bennett DA, De Jager PL (2012) A coding vari- 1654
ant in CR1 interacts with APOE-4 to influence cognitive 1655
decline. Hum Mol Gen 21, 2377-2388. 1656
[95] Hagenaars SP, Harris SE, Davies G, Hill WD, Liewald 1657
DCM, Ritchie SJ, Marioni RE, Fawns-Ritchie C, Cullen B, 1658
Malik R; METASTROKE Consortium, International Con- 1659
sortium for Blood Pressure GWAS; SpiroMeta Consortium; 1660
CHARGE Consortium Pulmonary Group, CHARGE Con- 1661
sortium Aging and Longevity Group, Worrall BB, Sudlow 1662
CLM, Wardlaw JM, Gallacher J, Pell J, McIntosh AM, 1663
Smith DJ, Gale CR, Deary IJ (2016) Shared genetic aeti- 1664
ology between cognitive functions and physical and mental 1665
health in UK Biobank (N=112 151) and 24 GWAS consortia. 1666
Mol Psychiatry 21, 1624-1632. 1667
[96] Harris SE, Davies G, Luciano M, Payton A, Fox HC, 1668
Haggarty P, Ollier W, Horan M, Porteous DJ, Starr JM, 1669
Whalley LJ, Pendleton N, Deary IJ (2014) Polygenic risk 1670
for Alzheimer’s disease is not associated with cognitive 1671
ability or cognitive aging in non-demented older people. 1672
J Alzheimers Dis 39, 565-574. 1673
[97] Liang Y, Li H, Lv C, Shu N, Chen K, Li X, Zhang J, 1674
Hu L, Zhang Z (2015) Sex moderates the effects of the 1675
Sorl1 gene rs2070045 polymorphism on cognitive impair- 1676
ment and disruption of the cingulum integrity in healthy 1677
elderly. Neuropsychopharmacology 40, 1519-1527. 1678
